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ABSTRACT: 
 
Alzheimer’s disease (AD) is the most common cause of dementia and one of the leading 
sources of morbidity and mortality in the aging population wordwide. As the population 
ages, the incidence of this neurodegenerative disease will increase, and it will pose a major 
socio-economical challenge to all societies in the future. There is a prolonged 
presymptomatic period, even lasting for decades, between the very first biochemical 
changes occurring in the brain until the appearance of the clinical symptoms of AD. 
Extensive research efforts are being focused on the development of disease-modifying 
therapies that would directly influence the pathologic cascade leading ultimately to AD. 
However, one prerequisite for devising these disease-modifying therapies is that one must 
be able to identify incipient AD when it is still at a minimally symptomatic state i.e. before 
there are any irreversible alterations in brain structures. Therefore, new biomarkers to 
detect the pharmacologic effects of existing and novel AD therapeutic agents as well as new 
methods for early diagnosis are urgently needed. The aims of the present study were to 
advance our understanding of the morphological and pathophysiological alterations in 
prodromal AD, and to contribute to the identification of potential magnetic resonance 
imaging (MRI) markers for early interventions in AD such as functional MRI (fMRI) or MRI 
conducted after drug treatment (phMRI). 
The results of this study demonstrate that both the structure of the entorhinal cortex and 
the function of the posteromedial cortices are affected early in the course of AD, and 
furthermore these changes are strongly correlated. Thus, an evaluation of structural and 
functional alterations of the strongly interconnected entorhinal and posteromedial cortices 
may represent a potential tool for early identification of AD. 
The second part of the study revealed that the prefrontal attention/working memory 
systems are impaired in the early stage of the AD and that the effect of cholinergic 
stimulation, as reflected by the altered fMRI activity during a recognition memory task, 
depends on the clinical severity of the disease. Furthermore, the increased fMRI activation 
in brain areas sensitive for task demands after cholinergic stimulation is dependent on the 
presence of functional brain networks. This means that phMRI may be useful for 
identifying those AD patients likely to respond to treatment with cholinesterase inhibitors. 
phMRI may have clinically important applications in the study of future therapeutic agents, 
especially in conditions where some novel medication would be rather toxic or involve a 
non-oral delivery mode e.g. infusion. However, more research will be needed before one 
can anticipate major breakthroughs in the early diagnosis and treatment of AD.  
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TIIVISTELMÄ: 
 
Alzheimerin tauti (AT) on yleisin dementoiva sairaus ja yksi merkittävimmistä syistä 
ikääntyvän väestön sairastavuuden ja kuolleisuuden aiheuttajana. Sen esiintyvyys kasvaa 
väestön vanhetessa aiheuttaen kasvavaa sosioekonomista haastetta yhteiskunnille 
maailmanlaajuisesti. AT:n biokemiallisten muutosten käynnistymistä seuraa jopa 
vuosikymmenten pituinen periodi ennen kliinisten oireiden alkamista. Tutkimuksen 
kannalta merkittäviä resursseja on keskitetty taudin kulkuun vaikuttavien lääkkeiden 
kehittämiseen. Näiden tulevaisuuden hoitojen kannalta olisi kuitenkin optimaalista 
tunnistaa AT mahdollisimman aikaisin, jolloin palautumattomia muutoksia aivoissa ei 
vielä olisi ehtinyt tapahtua. Näin ollen tarvitaan pikaisesti uusia biomarkkereita nykyisen ja 
tulevan lääkehoidon vaikutuksien tunnistamiseen sekä uusia metodeja AT:n varhaiseen 
diagnostiikkaan. Tämän tutkimuksen tavoitteena oli parantaa ymmärrystä AT:n 
morfologisten ja patofysiologisten muutosten osalta ja kehittää potentiaalisia 
magneettikuvantamismarkkereita. 
Ensimmäisen osatyön tulokset osoittivat, että entorinaalisen aivokuoren rakenne ja 
posteromediaalisen aivokuoren toiminta olivat muuntuneet AT:n alkuvaiheessa ja että 
nämä löydökset kytkeytyivät voimakkaasti toisiinsa. Näin ollen rakenteellisten ja 
toiminnallisten muutosten tutkiminen näiltä vahvasti toisiinsa kytkeytyviltä aivoalueilta, 
saattaa osoittautua potentiaaliseksi menetelmäksi varhaisen AT:n diagnostiikan osalta. 
Osatöiden 2 ja 3 tulokset osoittivat ChEI:n aikaansaaman ja farmakologisen 
funktionaalisen magneettikuvantamisen (phMRI) havaitseman aivoaktivaation riippuvan 
AT:n kliinisestä vaikeudesta. Tulosten mukaan kolinergisen stimulaation aikaansaama aivo 
aktivaation voimistuminen tehtävän suorituksen kannalta oleellisilla alueilla oli 
riippuvainen toimivista aivoverkostoista ja edelleen positiivisesta ChEI vasteesta. Toisin 
sanoen phMRI voi olla hyödyllinen metodi arvioitaessa kolinergisen lääkityksen vastetta. 
Tässä tutkimuksessa käytetty phMRI metodi voi olla kliinisesti tärkeä tulevissa 
farmakologisissa tutkimuksissa kuten myös tulevaisuuden lääkeaineiden osalta tilanteissa, 
joissa lääkkeen hinta tai toksisuus aiheuttaa haasteita. Kokonaisuutena AT:n varhainen 
diagnostiikka ja hoito tarvitsee kuitenkin vielä paljon tutkimusta ennen merkittävää 
läpimurtoa. 
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1 INTRODUCTION  
Alzheimer’s disease (AD) is the most common cause for dementia. As the median age of 
population becomes older, the incidence of this neurodegenerative disease will continue to 
increase, posing a major socio-economical challenge to all societies. Extensive research efforts 
are being focused on the development of disease-modifying therapies that directly influence the 
pathologic cascade leading up to AD. Hand in hand with this search for novel therapies, much 
effort is being expended in identifying new biomarkers capable of detecting AD. It would be 
desirable that those new techniques could detect not only the pharmacological effects of 
existing AD drugs but also help in identifying novel AD therapeutic agents. The earliest AD-
related neuropathological changes may appear in the hippocampus (HC) and other medial 
temporal lobe (MTL) substructures years, or even decades, prior to the manifestation of full-
blown AD. Since it seems that future treatments will be disease modifying therapies not simply 
symptom alleviating as is the case with the current AD drugs, it is essential to identify incipient 
AD at a minimally symptomatic state i.e. before irreversible alterations in brain structure have 
occurred and thus there is an urgent need to devise novel methods for early AD diagnosis. 
In AD, the degeneration of cholinergic neurons in the basal forebrain nuclei gradually 
deprives the brain of an effective cholinergic input. This cholinergic denervation of the cerebral 
cortex and HC is recognized as being a major contributing factor to the development of the 
common clinical symptoms of AD, such as impaired recent episodic memory, as well as 
executive, complex attentional, and visuospatial functions (Lanctôt et al. 2003a, Trinh et al. 
2003). In addition to this cholinergic hypothesis, the amyloid cascade hypothesis (Selkoe 1991) 
states that Aβ42 peptides aggregate to form amyloid plaques, which lead to synaptic loss and 
cell death, reflected in elevated cerebrospinal fluid (CSF) levels of tau, thereby causing 
dementia. These two theories i.e. the amyloid cascade and cholinergic hypotheses, have 
dominated the study of AD treatment in recent decades. 
Cholinesterase inhibitors (ChEI), such as donepezil, galantamine, and rivastigmine, increase 
the amount of bioavailable acetylcholine by inhibiting its enzymatic degradation in the synaptic 
cleft. ChEIs are the current standard pharmaceutical therapies for AD in addition to the N-
methyl-D-aspartate antagonist, memantine. It has been demonstrated that the effect of 
pharmacotherapy on brain function during cognitive tasks can be monitored with so-called 
pharmacologic functional magnetic resonance imaging (phMRI) (Honey et al. 2004). 
Although much effort has been expended already, much more research will need to be 
conducted before we can expect any major breakthroughs in the early diagnosis and treatment 
of AD. In this respect, this study attempts to increase our understanding of AD 
pathophysiology, by investigating the possibilities of exploiting functional magnetic resonance 
imaging (fMRI) of posteromedial cortex linked with temporomedial atrophy and with the 
pharmacological effects of cholinesterase inhibitors (ChEI). The overarching goal of this study 
was to advance our understanding of the pathogenesis of AD and to devise and evaluate a 
novel phMRI method to be used not only with ChEI but also with other pharmacological 
agents. 
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2 REVIEW OF THE LITERATURE  
2.1 ALZHEIMER’S DISEASE 
2.1.1 Clinical features 
Alzheimer’s disease (AD) is the most common cause of dementia and one of the leading sources 
of morbidity and mortality in the aging population all around the word. There are convincing 
predictions that the number of AD patients will increase in the coming decades (Rocca et al. 
2011, Ganguli et al. 2005, Llibre et al. 2008, Prince et al. 2013, Hebert et al. 2013, Sosa-Ortiz et al. 
2012). In Finland, there are an estimated 120 000 individuals over the age of 65 years living with 
mild cognitive impairment; 35 000 with mild dementia and 85 000 with at least moderate 
dementia. Furthermore, 13 000 new dementia cases are diagnosed every year.   
There is a long presymptomatic period between the onset of biochemical changes in the brain 
and the appearance of true clinical symptoms of AD, the most characteristic of which is the 
progressive loss of episodic memory. Aside from age, the most clearly established risk factors 
for AD are a family history of dementia, rare dominantly-inherited mutations in genes that 
regulate the production or degradation of amyloid in the brain, and the apolipoprotein E 
(APOE) epsilon 4 (ε4) allele. 
The genetic basis of late-onset AD is complex, with susceptibility likely being conferred by a 
variety of more common but less penetrant genetic factors interacting with environmental and 
epigenetic influences. Although the most firmly established genetic risk factor for late-onset AD 
is APOE, the strength of its association may be modified by several factors, including gender, 
race, and vascular risk factors. 
Alzheimer disease is a neurodegenerative disorder of uncertain cause and pathogenesis that 
primarily affects older adults (Ballard et al. 2011) generally between the ages of 40-90 years. The 
symptoms of AD usually follow a progressive course, from the initial insidious impairment of 
episodic memory (i.e, memory for past personal experiences in a particular spatial and temporal 
context) followed by abnormalities in executive, visuospatial and language functions as well as 
the appearance of neurobehavioral problems. Memory impairment is a fundamental feature of 
AD and is often its earliest manifestation, but even when not the primary complaint, memory 
deficits can be detected in most patients with AD at the time of presentation. 
There is a distinctive pattern of memory impairment in AD (Markowitsch et al. 2012). For 
example, declarative memory for facts and events, which depends on mesial temporal and 
neocortical structures, is profoundly affected in AD, while subcortical systems supporting 
procedural memory and motor learning are relatively well spared until quite late on in the 
disease. Episodic memory, i.e. memory of specific events and contexts, is more profoundly 
impaired in early AD whereas the type of memory needed for handling vocabulary and 
concepts (semantic memory) often becomes impaired somewhat later. Semantic memory is 
encoded in neocortical (nonmesial) temporal regions. With respect to episodic memory, there is 
a distinction between immediate recall, memory for recent events, and memory of more distant 
events. Thus, the memory for recent events, served by the HC, entorhinal cortex, and related 
structures in the mesial temporal lobe, is prominently impaired in early AD (Scoville et al. 1957, 
Zola-Morgan et al. 1986, Peters et al. 2009). In contrast, immediate memory, which is encoded in 
the sensory association and prefrontal cortices, is spared early on, as are memories that have 
been consolidated for long periods of time, which can be recalled without HC function.  
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2.1.3 Neuropathology of AD 
It is increasingly acknowledged that the pathological changes that lead to the eventual 
diagnosis of symptomatic AD begin long before there is sufficient cognitive impairment to 
warrant a clinical diagnosis of the disease (Jack et al. 2009, Price et al. 2009). The molecular 
pathology of AD is complex. However, amyloid plaques and neurofibrillary tangles are the two 
pathological hallmarks of AD (Holtzman et al. 2011). The amyloid cascade hypothesis and the 
cholinergic hypothesis have stimulated much of the research conducted into AD over the last 
decades. 
In 1974, Drachman and Leavitt (Drachman et al. 1974) postulated that memory was related to 
the cholinergic system and was age dependent. In AD, the degeneration of cholinergic neurons 
in the basal forebrain nuclei progressively deprives the brain of its cholinergic input. This 
cholinergic denervation of the cerebral cortex and HC is a major contributing factor to the 
development of the common clinical symptoms of AD, such as impaired recent episodic 
memory, as well as executive, complex attentional, and visuospatial functions (Lanctôt et al. 
2003a, Trinh et al. 2003). According to the cholinergic hypothesis, AD was conceptualized as a 
cholinergic disease, similar in the way that Parkinson’s disease is considered a dopaminergic 
disease (Coyle et al. 1983). 
In its simplest form, the amyloid cascade hypothesis (Selkoe, 1991) states that Aβ42 peptides 
aggregate to form amyloid plaques, which lead to synaptic loss and cell death, reflected in 
elevated CSF tau, thereby causing dementia. Both the pathology and clinical expression of AD 
result from the increased production or impaired clearance of particular toxic Ab species, 
particularly oligomers, produced by sequential b- and c-secretase cleavage of the trans-
membrane protein amyloid precursor protein. Recent reviews, however, have indicated that the 
process may not be that straightforward (Holtzman et al. 2011, Hyman 2011, Pimplikar 2009, 
Small et al. 2008, Struble et al. 2010). 
The cognitive impairment in patients with AD is closely associated with the progressive 
degeneration of the limbic system (Arnold et al. 1991, Klucken et al. 2003), neocortical regions 
(Terry et al. 1981), and the basal forebrain (Teipel et al. 2005). This neurodegenerative process is 
characterized by early damage to the synapses (Masliah et al. 1993, Masliah et al. 1994, Masliah 
2000, Crews et al. 2010) with retrograde degeneration of the axons and the ultimate atrophy of 
the dendritic tree (Coleman et al. 2002, Higuchi et al. 2002, Grutzendler et al. 2007, Perlson et al. 
2010) and perikaryon (Hyman et al. 1986, Lippa et al. 1992). Synaptic loss, plasticity changes, 
neuronal loss, and the presence of soluble microscopic oligomeric forms of Aβ and even of tau, 
are all likely to contribute to the progressive neural system failure that occurs over decades. 
Recent concepts on the pathological cascade of AD have indicated that the earliest AD-
related neuropathological changes may appear in the HC and other MTL substructures years, 
or even decades, prior to the manifestation of full-blown AD (Ohm et al. 1995, Selkoe 2001, 
Selkoe 2002). 
2.1.3 Diagnosis 
The definitive diagnosis of Alzheimer disease (AD) requires a histopathological evaluation, and 
thus most epidemiologic studies of AD rely on clinical criteria to define cases. The clinical 
criteria for a diagnosis of probable AD have changed over time, for example much of the older 
literature has either not distinguished between AD and other forms of dementia or utilized 
relatively small case-control type studies in selected populations. The diagnosis of AD is 
commonly based on the DSM-IV-TR criteria for the dementia of the Alzheimer’s type and/or the 
criteria proposed by the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) 
work group (McKhann et al. 1984). The NINCDS-ADRDA criteria are presented in Table 1. In 
general, they require a gradual onset between ages 40-90, symptoms of dementia syndrome 
affecting memory and other cognitive functions and the absence of any other reason for the 
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cognitive decline. In the research setting, the diagnosis of AD is most often a two-step process 
based on the presence of dementia by the DSM-IV-TR criteria and fulfillment of the criteria for 
probable AD of the NINCDS-ADRDA work group. In the clinical environment, the diagnosis is 
usually based on the NINCDS-ADRDA criteria and is a probabilistic definition of either 
probable or possible AD, which can be further verified to definite diagnosis by autopsy, or 
rarely by brain biopsy.  
Table 1. NINCDS-ADRDA clinical criteria for Alzheimer's disease (AD), applied from McKhann et al. 
(1984) 
Probable AD Possible AD Definite AD  
Dementia established by 
clinical examination and 
documented by MMSE or a 
similar cognitive scale, and 
confirmed by 
neuropsychological tests  
 
May be made on the basis of the 
dementia syndrome, in the absence of 
other neurologic, psychiatric, or 
systemic disorders sufficient to cause 
dementia, and in the presence of 
variations in the onset, in the 
presentation, or in the clinical course  
 
The clinical criteria for 
probable Alzheimer’s 
disease  
 
Deficits in two or more areas 
of cognition  
 
May be made in the presence of a 
second systemic or brain disorder 
sufficient to produce dementia, which 
is not considered to be the cause of 
the dementia  
 
Histopathologic evidence 
obtained from a biopsy or 
autopsy 
Progressive worsening of 
memory and other cognitive 
functions  
 
Should be used in research studies 
when a single, gradually progressive 
severe cognitive deficit is identified in 
the absence of other identifiable cause  
 
 
No disturbance of 
consciousness  
 
  
Onset between ages 40 and 
90, most often after age 65  
 
  
Absence of systemic 
disorders or other brain 
diseases that in and of 
themselves could account for 
the progressive deficits in 
memory and cognition  
  
MMSE = Mini-Mental State Examination  
There are several problems with the 1984 criteria (McKhann et al. 1984), i.e. the diagnosis of 
AD is clinico-pathological, cannot be certified clinically and needs a post-mortem confirmation 
to be ascertained. The diagnosis of AD can only be ‘probable’ and made when the disease is 
advanced and reaches the threshold of dementia. Thus the criteria needed to be updated to 
increase specificity and to help with early diagnosis. 
 Since the publication of the original diagnostic criteria for AD (McKhann et al. 1984), the 
knowledge about AD pathology has increased tremendously leading to the proposal of 
improved criteria for AD for use in research (Dubois et al. 2007). The International Working 
Group (IWG) of dementia experts’ guidelines were updated in 2010 to address atypical clinical 
presentations of AD and to identify clinically asymptomatic individuals who are positive for the 
biomarkers of AD pathology (Dubois et al. 2010). At the same time, the National Institute on 
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Aging (NIA) of the National Institutes of Health in the United States, in partnership with the 
Alzheimer’s Association, convened three work groups beginning in 2009 to update the original 
standards which had been published 25 years earlier (Albert et al. 2011, McKhann et al. 1984, 
McKhann et al. 2011, Sperling et al. 2011). The new criteria were built around the core feature of 
episodic memory impairment accompanied by a positive biomarker or genetic finding in 
addition to the exclusion of other reasons for the symptoms. 
In 2012, an international group of investigators with experience in the clinical diagnosis of 
AD met at the Key Symposium in Stockholm and developed recommendations for harmonized 
clinical diagnostic criteria for AD (Morris et al. 2014). These harmonized diagnostic criteria were 
intended to improve the concordance between NIA and IWG sets of criteria, to simplify and 
standardize AD terminology, and move towards etiologically based diagnoses. 
As new knowledge is acquired regarding the pathophysiology of AD, its progression in 
heterogeneous populations and on the advantages and disadvantages of different biomarkers in 
the diagnosis, there will be a need to revisit these guidelines on a regular basis, perhaps every 3-
5 years. 
2.2 ALZHEIMER’S DISEASE TREATMENT 
2.2.1 AD treatment  
Currently, there is only symptomatic treatment available for AD patients, but in the future, it is 
hoped that there will be disease-specific, preferably disease-modifying, treatments. The 
development of AD drugs has mostly been based on amyloid hypothesis and cholinergic 
hypothesis. 
The amyloid hypothesis has led to the development of drugs which can disrupt the amyloid 
cascade (Gilman et al. 2005, Golde et al. 2011). Although simple in concept, the validation and 
development of amyloid drug targets has been complex in practice. Despite extensive research, 
no validated drug target has been developed for AD based on the amyloid cascade (Gilman et 
al. 2005, Mangialasche et al. 2010, Schneider et al. 2014). 
Early on, acetylcholine precursors were found to be ineffective (Etienne et al. 1981, Thal et al. 
1981) and postsynaptic cholinergic receptor agonists exerted unacceptable side effects (Bodick 
et al. 1997). In contrast, the results of studies with cholinesterase inhibitors (ChEIs) have been 
more encouraging, even in patients suffering from non-AD dementias. 
The results of trials of drugs for other targets have been disappointing. For example, 
although well-reasoned and based on convincing preclinical studies, anti-inflammatory agents, 
conjugated oestrogens, secretase inhibitors and Ab vaccines have had unexpected ‘opposite’ 
(i.e. cognition-impairing) effects and thus failed in trials intended to be confirmatory. Despite 
the evaluation of numerous potential treatments in clinical trials, only ChEIs and memantine 
have shown sufficient safety and efficacy to achieve marketing approval at an international 
level. 
2.2.2 Cholinesterase inhibitors 
In AD, the degeneration of cholinergic neurons in the basal forebrain nuclei progressively 
deprives the brain of its cholinergic input. This cholinergic denervation of the cerebral cortex 
and HC is a major contributing factor to the development of the common clinical symptoms of 
AD, such as impaired recent episodic memory, as well as executive, complex attentional, and 
visuospatial functions (Lanctôt et al. 2003a, Trinh et al. 2003). ChEIs, such as donepezil, 
galantamine, and rivastigmine, increase the amount of bioavailable acetylcholine by inhibiting 
its enzymatic degradation within the synaptic cleft; these drugs are the current standard 
pharmaceutical therapies for AD in addition to the N-methyl-D-aspartate antagonist, 
memantine. The mechanism of action of memantine is distinct from those of the cholinergic 
agents. Memantine may be beneficial not only as monotherapy but also when used in 
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combination with ChEIs (Tariot et al. 2004, Porsteinsson et al. 2008). However, this doctoral 
study has focussed on ChEIs. 
The ChEIs are effective for improving or stabilizing cognitive and neurobehavioral 
performance. Therapy with these compounds can be continued almost indefinitely. However, 
while these drugs may achieve a clinical benefit in patients with moderately advanced disease 
(Feldman et al. 2001), the medication is usually discontinued when a patient has progressed to 
advanced dementia. 
The average benefit of ChEIs in patients with dementia is a minor improvement in cognition 
and activities of daily living (Erkinjuntti et al. 2004, Aarsland et al. 2002, Wilkinson et al. 2003, 
Black et al. 2003, Doody et al. 2001; Kaduszkiewicz et al. 2005, Lanctôt et al. 2003a, Richie et al. 
2004). According to previous studies, it seems that at least every third treated patient does not 
gain any clinically meaningful benefit from ChEI treatment (Davis et al. 1999, Rogers et al. 1998, 
Rösler et al. 1999, Wilcock et al. 2000, Cummings 2003, Clark et al. 2003), while a smaller 
proportion (perhaps as many as one in five) may show a greater than average response (≥7 
point ADAS-cog improvement) (Langa et al. 2004, Grossberg et al. 2003). In the clinic, it is 
difficult to predict who will respond to treatment. However, even patients with severe AD may 
benefit from ChEIs (Burns et al. 2004), some subjects may even enjoy 5 years of beneficial effects 
(Bullock et al. 2005a).  
Studies on ChEIs including donepezil, rivastigmine, and galantamine have shown modest 
improvements in the behavioral symptoms (Rodda et al. 2009). Whether these drugs 
significantly improve long-term outcomes, such as the need for nursing home admission or 
maintaining critical activities of daily living (ADL), remains in doubt, since the evidence is 
conflicting (Trinh et al. 2003, Courtney et al. 2004, Schneider 2004, Lopez et al. 2002). 
In the clinic, it is difficult to predict who will respond to treatment. Although, no specific 
tests are available to identify patients likely to respond to these drugs, a number of clinical 
features have been proposed as possible response predictors, including younger age, faster rate 
of progression, moderate rather than mild level of cognitive dysfunction, the presence of 
symptoms suggesting Lewy body pathology, concomitant vascular pathology and brain 
perfusion changes after a testing dose as well as the appropriate neuropsychological profile and 
an initial clinical response to treatment (Bullock et al. 2005b, Farlow et al. 2001, Farlow et al. 
2005, Lanctôt et al. 2003b). Plasma beta amyloid levels after treatment, apolipoprotein E 
genotype, SPECT, MRI, and PET imaging results have also been evaluated as biological markers 
of responsiveness to ChEI (Lanctôt et al. 2003b, Sobow et al. 2007, Hongo et al. 2008).  
There are several possible reasons to explain why ChEIs are not as effective as expected in all 
patients with AD. AD is a multifactorial disease and a disease of multiply connected brain 
systems with different neurotransmitters and properties. The cholinergic deficit in AD is 
thought to be evidence for a loss of acetylcholine-producing (presynaptic) neurons, and thus 
one cannot expect that there will be little benefit from these drugs if the damage has extended to 
the neurons that are cholinergically post-synaptic. In these situations, attempts to augment 
cholinergic activity may not be able to counteract effects occurring downstream in the 
pathophysiology of AD. 
2.3 IMAGING IN ALZHEIMER’S DISEASE 
2.3.1 Structural Imaging in Alzheimer’s disease 
Magnetic resonance imaging (MRI) is the recommended brain imaging method in the 
evaluation of patients with suspected AD (Knopman et al. 2001). The advantage of structural 
neuroimaging is that it can detect treatable causes of dementia and to differentiate between the 
various dementia subtypes. Structural imaging visualizes physical alterations in the properties 
of brain tissue that occur in aging and various disease states. Brain MRI can reveal potential 
alternative diagnoses including cerebrovascular disease, other structural diseases such as 
 
 
 
8 
chronic subdural hematoma, cerebral neoplasm, normal pressure hydrocephalus, trauma, 
infections, inflammation, edema, and regional brain atrophy suggestive of frontotemporal 
dementia. The MRI findings in AD include both generalized and focal atrophy, as well as white 
matter lesions. In general, these findings are nonspecific. However, a number of investigators 
have correlated reduced HC volume with AD (Whitwell et al. 2012, van de Pol et al. 2006, 
Barkhof et al. 2007, Whitwell et al. 2008, Kantarci et al. 2010). Unfortunately, HC atrophy also 
occurs in other pathological conditions such as mesial temporal sclerosis, temporal lobe 
epilepsy, and certain vascular insults, and thus it should not be considered as pathognomonic 
of AD. HC atrophy is nevertheless supportive of an AD diagnosis, and its complete absence in a 
patient with dementia should at least raise a suspicion of some alternative diagnosis other than 
AD. A typical symmetric pattern of cortical atrophy predominantly affecting the medial 
temporal lobes with a relative sparing of the primary motor, sensory, and visual cortices, is 
considered to be strongly suggestive of AD (Jack et al. 2010; Risacher et al. 2009; Weiner et al. 
2013).  
The potential of brain imaging has expanded rapidly with new modalities and novel ways of 
acquiring and analysing the images. Various automated methods for measuring cortical 
thickness (CTH) from MRI scan have been proposed as novel imaging markers for AD (Fischl 
and Dale 2000, Jones et al. 2000, Kabani et al. 2001, Kim et al. 2005, Lerch and Evans 2005, 
MacDonald et al. 2000). Longitudinal studies have revealed higher rates of cortical atrophy in 
patients with AD, particularly in the temporal lobe (Jack et al. 1999; deToledo-Morrell et al. 
2004; Devanand et al. 2008; Risacher et al. 2009). 
More advanced structural MRI techniques can also be used for investigation of dementia, 
often in a research context. Diffusion weighted (DWI) and diffusion tensor imaging (DTI) 
techniques measure the integrity of tissue and white matter tracts. According DWI/ DTI studies, 
AD patients have reduced fractional anisotropy and increased diffusion relative to healthy 
controls in many white matter structures throughout the brain (Fellgiebel et al. 2004; Rose et al. 
2006; Zhang et al 2007; Ibrahim et al. 2009). Magnetic resonance spectroscopy (MRS) is a 
noninvasive neurochemical technique allowing the measurement of biological metabolites in 
the target tissue. In AD patients, MRS techniques have revealed reduced N-acetylaspartate 
levels and increased myo-inositol relative to HCs throughout the brain, with the most 
significant changes in the temporal lobe and HC (Schuff et al. 2002; Chantal et al. 2004). Studies 
of brain perfusion with MRI have consistently demonstrated decreased perfusion or 
“hypoperfusion” in patients with AD, particularly in temporoparietal regions, as well as frontal, 
parietal, and temporal cortices (Harris et al. 1998). 
2.3.2 Functional imaging in Alzheimer’s disease 
Functional brain imaging with [18F] fluorodeoxyglucose positron emission tomography (FDG-
PET), functional MRI (fMRI), or perfusion single photon emission computed tomography 
(SPECT) can reveal distinct regions of low metabolism and hypoperfusion in AD. These areas 
include the HC, the precuneus and the lateral parietotemporal cortex (Peters et al. 2009, 
Minoshima et al. 1997, Silverman et al. 2001, Powers et al. 1992, Duara et al. 1986, O'Brien et al. 
2010, Hu et al. 2010). There are clinical studies suggesting that FDG-PET may be useful in 
distinguishing AD from frontotemporal dementia (Pickut et al. 1997, Ishii et al. 1998, Foster et 
al. 2007, Rabinovici et al. 2011). 
Amyloid PET tracers (eg, 11C-labeled Pittsburgh compound-B, Florbetapir F18, and others) 
that measure the amyloid lesion burden in the brain have been developed; these are new tools 
to aid in the diagnosis of AD in vivo, aid in evaluation of prognosis, and differentiate AD from 
other causes of dementia. In the published [11C]PiB studies, 96% of AD patients exhibited 
significant amyloid accumulation, measured as a “positive” [11C]PiB signal (Johnson et al. 
2012). Amyloid deposition occurs early in the disease and by the time that a sufficient cognitive 
decline has occurred to permit a diagnosis of AD, the brain amyloid burden is relatively stable 
and subsequent deposition is minimal (Klunk et al. 2006; Jack et al. 2009). Amyloid imaging is 
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accomplished by the injection of trace amounts of small molecules that bind with high affinity 
to fibrillar beta amyloid. These molecules are coupled to the positron-emitting F18 to permit 
their detection and localization in the brain. An amyloid PET scan that is considered as negative 
decreases the likelihood that a patient with dementia actually has AD. However, a positive scan 
is not sufficient to allow a diagnosis of AD, since amyloid plaques are also present in other 
neurodegenerative diseases and in the non-demented elderly (Silverman et al. 2002, Jagust et al. 
2007). 
At present, the cost and availability limit the widespread use of functional and molecular 
neuroimaging. PET neuroimaging studies are some of the most expensive tests employed in the 
evaluation of dementia and are certainly some of the most technically demanding. 
Measurement of cerebral perfusion or metabolism is helpful when a differential diagnosis of 
AD and frontotemporal dementia is required, and in the evaluation of suspected AD in the 
context of mild cognitive impairment. 
2.3.3 fMRI 
During the past years, there has been a huge interest worldwide in fMR imaging of human 
cognition. fMRI can be used to gather information about brain processing of short (1-30 second) 
stimuli or tasks. Initially, fMRI was developed to measure changes in BOLD contrast between 
two conditions (eg, task and no task). Whereas fluoro-deoxy-d-glucose (FDG)-PET is thought to 
be primarily a measure of synaptic activity, BOLD fMRI is considered to reflect the integrated 
synaptic activity of neurons through changes in the MRI signal attributable to changes in blood 
flow, blood volume, and the blood oxyhemoglobin/deoxyhemoglobin ratio (Logothetis et al. 
2001). The fMRI technique most widely used to identify cerebral activation is based on imaging 
of the endogenous blood-oxygen-level-dependent (BOLD) contrast (Kwong et al. 1992, Ogawa 
et al. 1992). Hemoglobin is diamagnetic when oxygenated but paramagnetic when 
deoxygenated. The relative decrease in the amount of deoxygenated hemoglobin enhances the 
MRI signal locally in brain areas that have been activated while undertaking a particular 
cognitive task. The BOLD contrast thus represents hemodynamic changes indirectly reflecting 
the underlying cellular activity. The BOLD fMRI signal and neurovascular coupling linking 
cellular activity to hemodynamic changes are likely to undergo changes during healthy aging 
and during pathological processes related to neurodegenerative dementias (Bangen et al. 2009, 
D’Esposito et al. 2003, Iadecola et al. 2004). 
Much of the early fMRI work in MCI and AD focused on the pattern of fMRI activation in 
HC and related medial temporal lobe structures and involved the subject conducting tasks 
requiring intact episodic memory. The results have been quite consistent in patients with 
clinically diagnosed AD, showing decreased HC activity during the encoding of new 
information (Small et al. 1999; Rombouts et al. 2000; Kato et al. 2001; Gron et al. 2002; Machulda 
et al. 2003; Sperling et al. 2003; Remy et al. 2004; Golby et al. 2005; Hamalainen et al. 2007a). 
Several studies have also reported increased prefrontal cortical activity in AD patients (Grady et 
al. 2003; Sperling et al. 2003; Sole-Padulles et al. 2009), which has been interpreted as 
representing compensatory mechanism during HC failure. There are also longitudinal studies 
suggesting that the presence of hyperactivity at baseline is a predictor of rapid cognitive decline 
and loss of HC function (Bookheimer et al. 2000; Dickerson et al. 2004; Miller et al. 2008; O’Brien 
et al. 2010).  
2.3.4 Resting-state (‘default mode’) in fMRI 
In many task functional MR studies, reversed contrasts (i.e., focusing on decreased activity 
during task performance) have consistently revealed deactivation of regions in the precuneus, 
parietal cortex, and orbitofrontal regions (Damoiseaux et al. 2006; Gusnard et al. 2001; Vincent 
et al. 2007). Since this network seems most active in the absence of a task, the name default 
mode network (DMN) was coined (Raichle et al. 2001; Buckner et al. 2008). DMN brain areas 
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also overlap with the anatomy of those regions with the highest amyloid burden in AD patients 
(Buckner et al. 2005; Buckner et al. 2009; Klunk et al. 2004; Sperling et al. 2009).  
Both independent component analyses and “seed-based” connectivity techniques have 
revealed the robust intrinsic connectivity between the posteromedial nodes of the default 
network, with the HC. It has been hypothesized that this functional connectivity is impaired in 
MCI and AD (Bai et al. 2008; Greicius et al. 2004; Koch et al. 2010; Rombouts et al. 2005; 
Rombouts et al. 2009; Sorg et al. 2007) over and above the more general age-related disruption 
of large-scale networks (Andrews-Hanna et al. 2007; Damoiseaux et al. 2008). Recent studies 
have also indicated that there are markedly abnormal responses detected in the default network 
during memory tasks in clinical AD patients and in subjects at risk for AD (Lustig et al. 2004; 
Celone et al. 2006; Petrella et al. 2007a; Pihlajamäki et al. 2008; Pihlajamäki et al. 2009). 
Interestingly, these same default network regions tend to manifest a paradoxical increase in 
fMRI activity in both at-risk groups and clinical AD patients (Fleisher et al. 2009; Petrella et al. 
2007b; Pihlajamäki et al. 2008; Sperling et al. 2010). 
2.3.5 Posteromedial cortex hypometabolism and temporomedial atrophy 
Hypometabolism of the posteromedial association cortices has been consistently demonstrated 
in previous [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) studies in 
patients with early Alzheimer’s disease (AD) (Rapoport 1999, Minoshima et al. 1997, Herholz et 
al. 2002, Mosconi et al. 2008). Another characteristic imaging finding of early AD is atrophy of 
the medial temporal lobe (MTL) memory structures, in particular in the entorhinal cortex (Jack 
et al. 1999, Killiany et al. 2000, Dickerson et al. 2001, Pennanen et al. 2004). The MTL, but not the 
posteromedial cortical regions, is affected early in the course of AD by neuropathological 
alterations such as neurofibrillary tangles, selective neuronal loss, and synaptic alterations 
(Hyman et al. 1984, Braak et al. 1991, Gómez-Isla et al. 1996, Kordower et al. 2001, Scheff et al. 
2007). Given the strong anatomical connectivity between the MTL and the posteromedial 
cortices (Kobayashi et al. 2003, Parvizi et al. 2006, Kobayashi et al. 2007), posteromedial 
metabolic abnormalities have been proposed to reflect remote effects of MTL pathology. This 
hypothesis has been supported by studies conducted in non-human primates (Meguro et al. 
1999, Blaizot et al. 2002), and by a post-mortem study in AD patients (Bradley et al. 2002), which 
revealed significant metabolic and perfusion abnormalities in the posteromedial regions caused 
by MTL lesions. However, few in vivo studies have tested this hypothesis in humans.  
Interestingly, the same association cortical regions that are vulnerable to hypometabolism in 
AD have demonstrated high resting-state, or ‘default mode’, activity and a predilection for task-
induced deactivation responses in fMRI studies in healthy subjects (Gusnard et al. 2001, 
Mazoyer et al. 2001, Raichle et al. 2001, Buckner et al. 2005, Buckner et al. 2008). There are 
reports that the fMRI task-induced deactivation pattern is disrupted in mild cognitive 
impairment (MCI) and AD patients as compared with elderly controls in the posteromedial core 
regions of the default mode network (Lustig et al. 2003, Greicius et al. 2004, Rombouts et al. 
2005, Petrella et al. 2007a, Petrella et al. 2007b, Pihlajamäki et al. 2009). The relationship of 
impaired posteromedial fMRI activity to local and remote morphological changes in prodromal 
AD has yet to be investigated.  
2.3.6 Pharmacologic functional magnetic resonance imaging in AD 
The effect of pharmacotherapy on brain function during cognitive tasks can be investigated 
using pharmacologic functional magnetic resonance imaging (phMRI) (Honey et al. 2004). It has 
been demonstrated in healthy young subjects that phMRI can detect pharmacologically induced 
effects with reasonable test-retest reliability (Sperling et al. 2002).  
To date, several phMRI studies have demonstrated altered brain activation in elderly subjects 
and AD patients after acute or prolonged treatment with ChEI (Saykin et al. 2004, Kircher et al. 
2005, Goekoop et al. 2004, Goekoop et al. 2006, Grön et al. 2006, Shanks et al. 2007). Some of 
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these studies (Saykin et al. 2004, Goekoop et al. 2004, Goekoop et al. 2006, Grön et al. 2006) also 
included subjects with MCI – a putative prodromal state of AD – who showed similar effects as 
AD patients, although specific regional differences in the phMRI response patterns between 
MCI and AD patients have also been reported (Goekoop et al. 2006).  
Previous phMRI studies in AD patients during various cognitive tasks have revealed that 
ChEI induces both increases and decreases in brain activation patterns. For example, during a 
face-encoding task after a single dose of rivastigmine, AD patients displayed increased fMRI 
activation in the fusiform gyrus, which was interpreted to reflect enhanced visual face 
processing (Rombouts et al. 2002). Enhanced face processing was also described in a study of 
healthy subjects, in these experiments increased activity was observed in the occipital visual 
areas, but decreased activity was observed in the prefrontal areas after treatment with the 
traditional ChEI, physostigmine (Furey et al. 2000). During a face recognition memory task, AD 
patients exhibit increased HC and cortical fMRI activity after acute galantamine treatment, 
which reversed to decreased activity after prolonged (5 days) drug treatment (Goekoop et al. 
2006). Patients with MCI treated for a mean of 6 weeks with donepezil also had increased 
frontal activation while performing a working memory task (Saykin et al. 2004). Thus, the 
results of previous functional imaging studies suggest that the positive pharmacologic effects of 
ChEI are region-specific rather than global (Goekoop et al. 2006, Nordberg et al. 1998, Kaasinen 
et al. 2002, Nobili et al. 2002), and depend on the cognitive process being studied, as well as the 
genotype and age of the patients (Honey et al. 2004). The effects of ChEIs observed in previous 
phMRI studies have also been considered to be dependent on the subject’s cognitive capacity 
and this is related to the stage of the disease, reflecting the functional status of the 
neurotransmitter system under investigation (Honey et al. 2004, Saykin et al. 2004, Goekoop et 
al. 2004, Goekoop et al. 2006, Thiel et al. 2002, Fu et al. 2004).  
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3 AIMS OF THE STUDY 
There is a long presymptomatic period between the onset of biochemical changes in the brain 
and the appearance of clinical symptoms of AD. The aim of this study was to advance our 
understanding of the morphological and pathophysiological alterations in prodromal AD, and 
to contribute to the identification of potential MRI markers for early interventions in AD. More 
specifically: 
1. The goal of the first study was to test the hypothesis that the posteromedial dysfunction 
would be related to the extent of MTL atrophy reflecting underlying neuropathological 
changes within a group of elderly individuals who represented a cognitive spectrum 
ranging from normal aging through amnestic MCI up to mild AD. 
2. The second study evaluated fMRI activation of newly diagnosed mild AD patients with 
no history of ChEI use after placebo, and after either acute or four weeks’ treatment with 
ChEI. It was also investigated whether fMRI could clarify the reasons for the 
heterogeneous ChEI treatment responses. 
3. The third study was conducted to develop possible methods to identify patients likely to 
respond to ChEI treatment. 
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4 SUBJECTS AND METHODS 
4.1 SUBJECTS AND METHODS: STUDY I 
A total of 55 right-handed elderly individuals participated in this study (Table 2). There were 21 
older controls, 18 subjects with MCI, and 16 patients with mild AD. Control and MCI subjects 
were recruited from the third follow-up visit of a population-based longitudinal study being 
organized in the Brain Research Unit, University of Eastern Finland (Hänninen et al. 2002, 
Tervo et al. 2004). The controls were classified as cognitively intact on the basis of both a 
thorough neuropsychological evaluation and a clinical dementia rating (CDR) score (Morris et 
al. 1997) of zero. The MCI subjects had a total CDR score of 0.5, at least 0.5 in the CDR memory 
subcategory, and were classified as having ‘amnestic multidomain’ MCI (Petersen et al. 2001). 
The AD patients were recruited from the neurological outpatient clinic of Kuopio University 
Hospital. They underwent careful diagnostic assessment, including neuropsychological testing, 
laboratory sampling, computed tomography or magnetic resonance imaging of the brain, and a 
clinical and neurological examination. Diagnoses were made by experienced neurologists 
according to the NINCDS-ADRDA criteria for probable AD (McKhann et al. 1984). Details of 
the subject selection criteria and of the extensive neuropsychological testing have been 
presented by Hämäläinen et al. (2007a); this report contained information about 50 of the 55 
subjects included in the present study. The following cognitive measures were used for the 
purposes of this study: Mini-Mental State Examination (MMSE), Boston naming, verbal fluency 
(PAS), trail making A and C, as well as word list recall (immediate and delayed recall) from the 
CERAD Neuropsychological Assessment Battery.  
None of the subjects had a history of neurological or psychiatric disease other than AD. At 
the time of the MRI experiment, 10 of the 16 AD patients were receiving cholinesterase inhibitor 
treatment: six were being treated with donepezil, one was on rivastigmine, and three were 
receiving galantamine. The patients were not taking any other medications known to affect 
cognition. Informed written consent was acquired from all subjects according to the Declaration 
of Helsinki. In the case of AD patients, consent was obtained in the presence of a care-giver. The 
study was approved by the Ethics Committee of Kuopio University Hospital.  
Table 2. Demographic, neuropsychological and functional MRI behavioural characteristics of the 
study subjects. 
 Older controls MCI subjects         AD patients          ANOVA 
n Mean ± SD 
(range) 
n Mean ± SD  
(range) 
n Mean ± SD  
(range) 
P-value 
(F-value) 
Demographics 
    Age, y 21 70.8 ± 4.8      
(64 - 79) 
18 72.2 ± 7.0      
(57 - 82) 
16 74.8 ± 5.4*      
(63 - 83) 
0.121  
(2.196) 
    Female / male 21 17 / 4 18 11 / 7 16 11 / 5  
    Education, y  21 7.7 ± 2.8          
(4 - 15) 
18 7.7 ± 2.4          
(4 - 13) 
16 8.9 ± 3.4          
(6 - 15) 
0.350  
(1.072) 
Neuropsychology 
    MMSE 21 27.6 ± 2.0      
(23 - 30) 
18 24.8 ± 3.7*     
(17 - 29) 
16 21.8 ± 3.3*#    
(15 - 29) 
<0.00001 
(17.402) 
    Clinical Dementia 
Rating total 
21 0.0 ± 0.0 18 0.5 ± 0.0* 16 0.9 ± 0.2*#   
(0.5 - 1) 
<0.00001 
(247.236) 
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Clinical Dementia 
Rating sum-of-boxes 
21 0.1 ± 0.2          
(0 - 0.5) 
15 1.5 ± 0.6*      
(0.5 - 2.5) 
4 3.5 ± 1.0       
(2.0 - 4.0) 
<0.00001 
(89.639) 
    Word list delayed recall 20 6.5 ± 1.4          
(3 - 9) 
17 4.4 ± 1.2*         
(2 - 6) 
11 1.9 ± 1.6*#       
(0 - 4) 
<0.00001  
(41.957) 
    Word list savings % 20 85.1 ± 14.2    
(50 - 100) 
17 67.4 ± 16.7*    
(38 - 86) 
11 38.4 ± 31.2*#    
(0 - 80) 
<0.00001 
(19.304) 
    Trail making test A 20 47.0 ± 13.7    
(29 - 78) 
18 65.6 ± 23.7*    
(40 - 120) 
11 74.7 ±35.3*    
(33 - 150) 
0.006 
(5.689) 
    Trail making test C 20 119.3 ±61.2    
(58 - 300) 
17 206.7 ± 74.3*   
(87 - 300) 
7 248.9 ± 87.4*  
(119 - 300) 
0.0001 
(11.693) 
    Boston naming 20 13 ± 1.7         
(10 - 15) 
16 10.8 ± 2.1*       
(8 - 15) 
7 11.1 ±2.7         
(8 - 15) 
0.006 
(5.772) 
    Verbal fluency (PAS) 20 43.2 ± 12.2    
(21 - 58) 
15 33.4 ± 13.6*    
(15 - 67) 
3 40.0 ± 16.5     
(23 - 56) 
0.106 
(2.396) 
Functional MRI behavioural results 
    Encoding 1 response 
% 
21 97 ± 8           
(67 - 100) 
18 93 ± 16          
(37 - 100) 
16 97 ± 5            
(83 - 100) 
0.477 
(0.752) 
    Encoding 2 response 
% 
21 98 ± 8          
(67 - 100) 
18 93 ± 18          
(27 - 100) 
16 94 ± 7             
(83 - 100) 
0.479 
(0.749) 
    Encoding 1 reaction  
time, ms 
19 1086 ± 300 
(737 - 1677) 
17 1418 ± 456*  
(795 - 2129) 
11 1310 ± 611    
(612 - 2718) 
0.082 
(2.651) 
    Encoding 2 reaction 
time, ms 
19 999 ± 320   
(605 - 1748) 
17 1179 ± 356   
(651 - 1895) 
11 1167 ± 542    
(571 - 2208) 
0.328 
(1.145) 
    Recognition hits % 21 78 ± 14         
(43 - 97) 
18 75 ± 13          
(47 - 100) 
16 60 ± 31            
(7 - 100) 
0.289 
(1.280) 
    Recognition false  
alarms % 
21 13 ± 11           
(0 - 43) 
18 20 ± 18            
(0 - 100) 
16 27 ± 24            
(7 - 100) 
0.016 
(4.547) 
Significant difference (p < 0.05) between study groups (Mann-Whitney U test): *vs. Older controls; #vs. MCI 
subjects. MMSE = Mini-Mental State Examination. 
4.1.1 Functional MRI stimulus (study I) 
The word list learning activation paradigm was designed to be incorporated as an fMRI 
modification of the clinically widely used word list memory tasks. Encoding and delayed recall 
of words are considered to be among the most sensitive neuropsychological tests for the 
identification of early AD (Albert et al. 1996). Prior to MRI scanning, all subjects underwent 
thorough training until they understood and could perform the computerized task 
satisfactorily. The paradigm consisted of four different alternating conditions: (i) encoding 
novel words (EN1); (ii) encoding repeated words (EN2); (iii) immediate cued recall (ICR); and 
(iv) visual fixation baseline (FIX). This study presents fMRI results of the comparisons between 
the encoding and baseline conditions; i.e. the results of the ICR condition are not reported here. 
During each EN1 block, five common Finnish nouns were shown for the first time within the 
experimental context. The length of the words was four to six letters, and they were presented 
one at a time in white 150-point Arial uppercase letters in the center of a field with a black 
background. EN1 blocks were immediately followed by EN2 blocks, during which the same 
five words were presented for the second time but in a randomly different order within each 
block. Two instruction slides preceded each set of EN1 and EN2 blocks, encouraging the 
subjects to read the words silently and press a response button with their right index finger 
once they had memorized the word. During the ICR blocks, the first two letters of each word 
were presented to the subjects, with the words again in a different order within each block. 
Subjects were instructed to press the button each time that they succeeded in retrieving the 
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corresponding word. During the FIX condition, subjects were simply instructed to focus their 
attention on a white crosshair on the black background. Both the ICR and FIX blocks were also 
preceded by instruction slides. In order to avoid head motion artefacts related to overt speech, 
subjects were asked to perform the task silently. The rationale for collecting behavioral data 
with the button presses was to verify that the subjects were concentrating on the task, and to 
obtain the subjects’ own estimate of their memory performance, while also ensuring that the 
task was feasible for MCI subjects and AD patients.  
The duration of the stimulus slides was 4.5 s, and the stimuli were separated by 0.5-s 
interstimulus intervals. Instruction slides were shown for 9.5 s, again followed by 0.5-s periods 
of visual fixation. The combination of the EN1, EN2, ICR and FIX blocks, including the 
intervening instruction slides, was repeated six times. At the end, while still in the scanner, the 
subjects underwent a recognition memory test, during which all of the 30 previously encoded 
words were randomly mixed with 30 new words. Subjects were instructed to press the response 
button with their index finger for each familiar word and not to press any buttons for new 
words. During the fMRI experiment, reaction times were successfully collected in 19 of 21 of 
OCs, 17 of 18 of MCI subjects, and 11 of 16 of AD patients. The missing reaction time data were 
attributable to technical equipment malfunctions. The total duration of the word list learning 
task was 21 min 55 s, equivalent to 526 whole-brain fMRI acquisitions. Visual stimuli were 
presented with a PC laptop computer equipped with presentation software (Neurobehavioral 
Systems, Albany, CA, USA), and the task was projected to the subjects via a video projector 
(Lite Pro 620; In Focus Systems, Wisconville, OR, USA) onto a translucent screen. The subjects 
viewed the stimuli through a mirror attached to the head coil. Responses were collected with a 
fiber-optic response box held in the right hand (Lumitouch; Lightwave Medical Industries, 
Burnaby, Canada). 
4.1.2 MRI data acquisition (study I) 
Subjects were scanned with a 1.5-T scanner (Magnetom Vision; Siemens Medical Systems, 
Erlangen, Germany) capable of echo-planar imaging (EPI) and a circular-polarized head coil. In 
order to minimize head motion, the subject’s head was carefully secured with foam rubber 
pads. Anatomical high-resolution images were acquired with a T1-weighted three-dimensional 
magnetization-prepared rapid acquisition gradient echo sequence with the following 
parameters: repetition time, 9.7 ms; echo time, 4.0 ms; flip angle, 10°; slice thickness, 1.0 mm; 
field of view, 256 mm; matrix size, 256 · 256; and pixel size, 1.0 · 1.0 mm. Functional imaging 
was conducted with a T2*-weighted gradient echo EPI sequence sensitive to blood- oxygen-
level-dependent (BOLD) contrast. The imaging parameters were as follows: repetition time, 
2500 ms; echo time, 70 ms; flip angle, 90°; slice thickness, 5 mm; interslice gap, 1 mm; field of 
view, 256 mm; matrix size, 64 · 64; and pixel size, 4.0 · 4.0 mm. Functional images were acquired 
in an oblique axial orientation aligned according to the anterior commissure (AC) - posterior 
commissure (PC) line. T2-weighted fluid attenuation inversion recovery images were acquired 
between the anatomical and functional images to exclude subjects with significant vascular 
pathology. The three-dimensional magnetization-prepared rapid acquisition gradient echo and 
fluid attenuation inversion recovery images were evaluated by an experienced 
neuroradiologist.  
4.1.3 Structural MRI data analysis (study I) 
Volumetry of the hippocampi and entorhinal cortices (Tables 5 and 6) was performed by 
manually outlining these structures in an anterior- to-posterior direction in the high-resolution 
T1-weighted anatomical images, with previously published methods (Soininen et al. 1994, 
Insausti et al. 1998) that have been utilized in several earlier studies (Juottonen et al. 1998; 
Pennanen et al. 2004). The mapping was performed by a single tracer who was blinded to the 
clinical data. An in-house-developed script was used to calculate the volumes, which were then 
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normalized to the intracranial area measured from a coronal slice at the level of the anterior 
commissure [(volume ⁄ intracranial area) x 100].  
Voxel-based morphometry (VBM) analysis was also performed with previously published 
methods (Pennanen et al. 2005, Hämäläinen et al. 2007b), which are briefly described below. The 
present study concentrated on VBM findings within the MTL and posteromedial cortices. First, 
a customized template was created: The origin of the spatial coordinates in individual images 
was set to the AC, and images were reoriented perpendicular to the AC-PC line and normalized 
to the Montreal Neurological Institute (MNI) space by 12-parameter affine transformation. 
Customized prior probability maps were created by partitioning the normalized images into 
gray matter (GM), white matter and cerebrospinal fluid segments, smoothing with an 8-mm 
Gaussian filter, and averaging the segmented images. Original images were then segmented 
and normalized to the customized template space through affine and non-linear 
transformations, medium regularization, and resampling to 2 x 2 x 2 mm3. The normalized 
images were further segmented into GM, white matter and cerebrospinal fluid segments. A 
modulation was performed on the segmented GM images by multiplying the GM voxels by the 
Jacobian determinants derived from the non-linear step of spatial normalization. The 
modulated GM images were smoothed with a 12-mm Gaussian kernel. Statistical analysis of 
differences in atrophy between the study groups (i.e. two- sample t-tests) was performed with 
spm2 software (Wellcome Department of Imaging Neuroscience, London, UK; 
http://www.fil.ion.ucl.ac. uk/spm), with age, gender and intracranial area included as nuisance 
covariates. The threshold for significant differences was set at a voxelwise uncorrected P < 0.01 
combined with an extent threshold of > 100 voxels. The final threshold for assessing statistical 
significance was a cluster-corrected P < 0.05. The same (cluster-corrected) statistical threshold 
was adopted in both VBM and fMRI analyses.  
4.1.4 Functional MRI data analysis (study I)  
Image preprocessing and data analysis were carried out with spm2. First, all functional volumes 
were spatially realigned and motion-corrected. Between-slice timing differences induced by 
differences in the acquisition order were corrected. Functional volumes were coregistered to T1-
weighted structural volumes oriented along the AC-PC line. Coregistration success was visually 
controlled for each subject individually. Normalization parameters determined from the 
structural volumes were used to spatially normalize each functional volume to a standard 
template volume based on the MNI reference brain. Spatial smoothing was performed with an 
8-mm Gaussian filter. Functional EPI volumes were sorted into EN1, EN2, ICR and FIX 
conditions, and the EN1 > EN2 and FIX > (EN1 + EN2) contrasts were defined for each 
individual. The EN1 > EN2 contrast (i.e. the contrast between processing novel and repeated 
words) was chosen as a relevant contrast to reveal MTL activation, on the basis of several 
previous fMRI studies (Rombouts et al. 2000, Sperling et al. 2003, Golby et al. 2005). The contrast 
FIX > (EN1 + EN2) (i.e. the contrast between active processing of novel and repeated words vs. 
fixation baseline) was considered to be the most meaningful for revealing fMRI task-induced 
deactivation responses, as the visual input and the cognitive and motor task instructions given 
to the subjects were identical during the EN1 and EN2 blocks. A canonical hemodynamic 
response function was used to model BOLD responses.  
Group-level fMRI data analysis was conducted with a general linear model on a voxel-by-
voxel basis. SPM2 random-effects analysis were applied utilizing one-sample t-tests for within-
group analyses and both anova and two-sample t-tests for between-group analyses. To 
investigate the relationship of entorhinal and hippocampal atrophy to the posteromedial BOLD 
fMRI signal, normalized volumes were used as covariates of interest across all subjects’ fMRI 
data, with age and gender included as nuisance variables.  
On the basis of a priori interest and results of previous FDG- PET and fMRI deactivation 
studies (Minoshima et al. 1997, Lustig et al. 2003, Nestor et al. 2003, Rombouts et al. 2005), fMRI 
data analysis was focused on two regions of interest (ROIs): (i) the MTL, including the 
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hippocampus and the entorhinal, perirhinal and parahippocampal cortices (Soininen et al. 1994, 
Insausti et al. 1998, Pruessner et al. 2002); and (ii) the posteromedial cortices, including the 
posterior cingulate, and retrosplenial and precuneal cortices (Cavanna et al. 2006, Parvizi et al. 
2006, Vogt et al. 2006). Structural regions provided by marsbar 0.41, a toolbox of spm2, were 
used to create these ROIs. fMRI data were thresholded with the same criteria as used for the 
VBM data – height threshold uncorrected, P < 0.01; extent threshold > 100 voxels; and threshold 
for reporting final statistical significance, P < 0.05, cluster-corrected. Tables 6, 7 and 8 give 
details of the peak t-values of significant activation and deactivation clusters, as well as the 
corresponding uncorrected P- values, number of voxels and MNI (x, y, z) coordinates.  
4.1.5 Statistical data analysis (study I) 
Statistical analysis of demographic, neuropsychological, volumetric and fMRI behavioral data 
was conducted with SPSS 15.0 (SPSS, Chicago, IL, USA), using one-way anova, the non-
parametric Mann-Whitney U-test, Spearman’s rank correlation, and the chi-square test. The 
level of statistically significant differences was set at a two-tailed P-value of < 0.05.  
4.2 SUBJECTS AND METHODS: STUDIES II-III 
A total of 23 right-handed patients newly diagnosed with mild AD that had no history of ChEI 
use were invited to participate in this researcher-initiated study (Tables 3-5). The patients in 
study 1 were not participating study 2. In study 2, three patients had to be excluded from the 
study: one due to nausea during the first imaging session, another due to nausea in the second 
imaging session, and a third subject due to an artifact caused by dental metal. Thus, the 20 
patients who were successfully scanned on all three occasions were included in the analysis. In 
study 3, five patients were excluded from the study: in addition to three patients, one was 
excluded due to noncompliance with the ChEI treatment and not attending the 12 months’ 
follow-up visit, and another died prior to the 12 months’ follow-up visit. Thus, the 18 patients 
who were successfully scanned on all three occasions were included in the analysis. 
 The AD patients were recruited from the neurologic outpatient clinic of Kuopio University 
Hospital. The patients underwent an extensive diagnostic workup, including clinical neurologic 
examination, neuropsychologic testing, laboratory tests (blood-count, liver, kidney-, and 
thyroid-function, blood glucose, serum electrolytes, cholesterol, triglycerides, vitamin B12, and 
erythrocyte folate), electrocardiography, and computed tomography or MRI of the brain. 
Diagnoses were made by an experienced neurologist according to the NINCDS-ADRDA criteria 
for probable AD (McKhann et al. 1984). Inclusion criteria for this study were probable AD 
according to the NINCDS-ADRDA criteria; a Clinical Dementia Rating (CDR) scale (Hughes et 
al. 1982) of 0.5 or 1, indicating very mild or mild AD; a treatment plan to medicate the patient 
with a ChEI; and no contraindications for medication. The exclusion criteria included a 
cognitive decline not due to AD, severe depression, other significant neurologic or psychiatric 
illness, unstable other disease, the presence of a pacemaker or some other metal object in the 
body, overweight (>120 kg), poor vision, claustrophobia, or the inability to perform a button 
press response during the fMRI task. 
The study had three separate fMRI sessions, which were named according to ChEI treatment 
they were receiving (placebo, acute and chronic). The first two fMRI evaluations were 
randomized in a double-blind manner such that the patient received either oral rivastigmine (3 
mg) or placebo in the fMRI experiment. The randomization was conducted by the pharmacist. 
Those subjects who received placebo in the first fMRI experiment, received rivastigmine in the 
second fMRI experiment and conversely, those who received rivastigmine in the first fMRI 
experiment, received placebo in the second fMRI experiment. There was a 1-week interval 
between the first and second fMRI experiments. After the second experiment, the patients were 
placed on a regimen of twice-daily rivastigmine (1.5 mg) for 4 weeks. The third fMRI evaluation 
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(chronic) was performed 4 weeks after the second experiment. Patients were not randomized 
for the third fMRI session because randomizing would have caused an unethical delay for 
initiating the ChI treatment. After the third fMRI assessment, the patients continued treatment 
with rivastigmine according to the clinician’s judgment, or if rivastigmine was not well 
tolerated, with some other ChEI. The clinical follow-up visits were scheduled at 6 and 12 
months and included a clinical neurologic examination, and CDR, MMSE, ADAS-Cog, CERAD, 
and ADCS-ADL assessments. At the 12 months’ follow-up, one patient was receiving donepezil 
5 mg, one was being treated with galantamine 16 mg and 16 patients were using rivastigmine 9 
mg. In addition, two patients were using quetiapine and 1 patient was taking an antidepressant.  
The clinical severity of AD was assessed using the CDR scale (McKhann et al. 1984), the 
Global Deterioration Scale (GDS) (Reisberg et al. 1982), and the Mini-Mental State Examination 
(MMSE) (Folstein et al. 1975). The Alzheimer's Disease Assessment Scale - Cognitive Part 
(ADAS-Cog) (Rosen et al. 1984) and the Consortium to Establish a Registry for Alzheimer's 
Disease (CERAD) Neuropsychological Assessment Battery (Morris et al. 1989) were used for the 
neuropsychologic assessment. In addition, activities of daily living were assessed using the AD 
Cooperative Study—Activities of Daily Living (ADCS-ADL) scale (Galasko et al. 1997). None of 
the patients had a history of neurologic or psychiatric disease other than AD, and none were 
using psychoactive medications. None of the patients had been medicated with a ChEI before 
the first acute fMRI experiment. 
The study was approved by the National Agency for Medicines and by the local Ethics 
Committee for human research. Written informed consent was obtained from all AD patients in 
the presence of a caregiver. The study was registered in ClinicalTrials.gov Identifier:  
NCT00627848; and in European Clinical Trials database Identifier: EudraCT2006-002182-39. 
Table 3. Demographic and neuropsychological characteristics of the participants. (Study 2) 
 Alzheimer's disease patients (n = 20) 
 Mean ± SD (Range) 
Age, years 76.1 ± 5.9 (61 - 84) 
Female / male 9 / 11 
Education, years 9.8 ± 4.1 (5 - 18) 
Mini-Mental State Examination 22.4 ± 3.0 (16 - 27) 
Clinical Dementia Rating total score 0.9 ± 0.2 (0.5 - 1.0) 
Clinical Dementia Rating sum-of-boxes 4.1 ± 1.9 (1.5 - 7.0) 
Global Deterioration Scale  3.7 ± 0.7 (2 - 5) 
CERAD Verbal Fluency 17.6 ± 6.4 (6 - 28) 
CERAD Naming 10.7 ± 3.2 (6 - 15) 
CERAD Word List Learning 11.7 ± 4.3 (1 - 17) 
CERAD Word List delayed, savings (%) 33.0 ± 30.2 (0 - 100) 
CERAD Word List delayed, recognition (%) 75.8 ± 11.0 (55 - 90) 
CERAD Copying 8.8 ± 1.7 (6 - 11) 
CERAD Copying, delayed savings (%) 36.9 ± 38.5 (0 - 100) 
CERAD Clock Drawing  3.3 ± 1.9 (1 - 6) 
ADAS-Cog 15.9 ± 8.5 (3 - 35) 
ADCS-ADL 55.2 ± 12.5 (36 - 74) 
ADAS-Cog = Alzheimer's Disease Assessment Scale - Cognitive Part; ADCS-ADL = Alzheimer’s Disease Cooperative 
Study - Activities of Daily Living; CERAD = Consortium to Establish a Registry for Alzheimer's Disease. 
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Table 4. Demographic and neuropsychological characteristics of the participants (study 3) 
 AD patients 
(n=18) Baseline         
AD patients (n=18) 
6 months’ follow up         
AD patients (n=18) 
12 months’ follow up             
 Mean ± SD 
(Range) 
Mean ± SD (Range) Mean ± SD (Range) 
Age, years 
75.5 ± 6.0 
(61 - 84) 
Female / male 9 / 9 
Education, years 10.1 ± 4.2 
(5 - 18) 
Mini-Mental State 
Examination 
22.6 ± 3.0           
(16 - 27) 
22.2 ± 3.5              
(14 - 27) 
22.3 ± 4.5                
(12 -28) 
MMSE change from baseline#  
-0.3 ± 3.0                 
(-6 - 4)             
Decline (7)           
Stable (3) 
Improvement(8) 
-0.2 ± 2.4                  
(-8 - 2)             Decline 
(6)           Stable (3) 
Improvement(9) 
Clinical Dementia Rating total 
score 
0.8 ± 0.2                    
(0.5 - 1.0) 
0.9 ± 0.4                    
(0.5 - 2) 
1.1 ± 0.7                    
(0.5 - 3) 
Clinical Dementia Rating 
sum-of-boxes 
4.1 ± 1.9             
(1.5 - 7.0) 
4.1 ± 2.3                  
(1 - 10) 
5.1 ± 3.8                  
(1 - 16) 
Global Deterioration Scale  3.6 ± 0.7              
(2 - 5) 
3.6 ± 0.6                  
(3 - 5) 
3.8 ± 0.9                  
(3 - 6) 
ADAS-Cog 14.9 ± 7.5             (3 - 30) 
13.5 ± 5.9                
(6 - 25) 
13.8 ± 7.1                  
(3 - 26) 
ADCS-ADL 56.8 ± 11.6         (41 - 74) 
66.3 ± 14.9            
(44 - 76) 
59.0 ± 21.4             
(27 - 71) 
MMSE changes at 6 and 12 months’ follow-up were compared to baseline#. Significant difference (p < 0.05) 
(Mann-Whitney U test) between baseline and 6 months’ / 12 months’ follow-up *. AD = Alzheimer's disease; 
ADAS-Cog = Alzheimer's Disease Assessment Scale - Cognitive Part; ADCS-ADL = Alzheimer’s disease 
Cooperative Study - Activities of Daily Living. 
Table 5. MMSE scores of individual patients at baseline and at the 12 months’ follow-up and the 
difference between these two scores (study 3). Patient four underwent an unexpectedly rapid 
decline for AD, which is taken into account in further analysis. 
Patient number MMSE 
baseline 
MMSE 12 
months 
MMSE 
change  
1 24 25  1 
2 18 17 -1 
3 22 24  2 
4 20 12 -8 
5 16 17  1 
6 21 20 -1 
7 20 16 -4 
8 23 25  2 
9 26 28  2 
10 20 21  1 
11 25 26  1 
12 27 27  0 
13 25 25  0 
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14 22 21 -1 
15 22 21 -1 
16 24 25  1 
17 27 27  0 
18 24 25  1 
AD = Alzheimer's disease; MMSE = Mini-Mental State Examination (Folstein et al. 1975). 
4.2.1 ChE inhibitor (studies II-III) 
Rivastigmine (Exelon®, Novartis Basel-Switzerland) was chosen for the experiment because of 
its strong and pseudo-irreversible acetylcholinesterase inhibiting properties. Rivastigmine is 
slowly reversible in comparison to other ChEIs and also inhibits butyrylcholinesterase. 
Rivastigmine undergoes non-hepatic metabolism, thus it is not subject to drug interactions and 
patient drop-outs are rare. The half-life of rivastigmine is 1 hour. The medication was given 2 
hours before the experiment in the placebo and acute exposures. The acute dose of rivastigmine 
was 3 mg and the chronic dose was 1.5 mg twice a day. This interventional study was 
researcher-initiated and not supported by the pharmaceutical industry.  
4.2.2 fMRI stimulus (studies II-III) 
Because cholinergic therapy is considered to be more advantageous for AD-related visuo-
attentional deficits than memory impairment per se (Bentley et al. 2008), a “face recognition” 
memory paradigm was used and modified for fMRI. Prior to each MRI scan, patients 
underwent thorough training in the task. The training and personnel were the same for all 
patients in all three fMRI sessions (P.S.M.). The paradigm comprised five consecutive visual 
stimuli: 1) a white fixation cross inside an ellipse as a cue (CUE) to indicate the start of one 
series; 2) a novel face (S1); 3) a white fixation cross (X1); 4) a second face (either the same as S1 
or a novel face) (S2); and 5) a green fixation cross (X2). Durations of the CUE, S1, and S2 were 2 
s, and durations of the X1 and X2 were each 6.0 s. Each series of the CUE/S1/X1/S2/X2 was 
repeated 30 times. The faces were similar in 15 face-pairs, and dissimilar in 15 face-pairs. The 
presentation order of the similar and dissimilar face-pairs was randomized. Half of the faces 
were female and half were male. All the faces had a neutral expression and were presented as 
photos. In each of the three experiments (placebo, acute, and chronic), the faces were different 
to avoid habituation effects. The total duration of the face recognition task was 9 min, 
corresponding to 180 fMRI whole-brain acquisitions. Visual stimuli were presented using 
Presentation 10.2 software (Neurobehavioral Systems, Albany, CA). The stimuli were projected 
to the patients via a video projector (Lite Pro 620, In Focus Systems Inc, Wisconville, OR) onto a 
translucent screen. Manual responses were collected using a fiber-optic response pad 
(Lumitouch, Lightwave Medical Industries, Burnaby, Canada). The patients were instructed to 
determine whether the faces in a face pair were similar or different, and respond during 
presentation of the green fixation cross with a button press using the right index finger for two 
similar faces and the right middle finger for two dissimilar faces. The rationale for collecting 
behavioral data with the button presses was to verify that subjects were concentrating on the 
task, and to obtain the subjects' own estimate of their memory performance, while also ensuring 
that the task was feasible for AD patients.  
The analysis of the data from the second and third publications concentrated on the fMRI 
results obtained during the recognition phase (S2) when patients were on the placebo, acute, 
and chronic ChEI regimens. 
4.2.3 MRI data acquisition (studies II-III) 
Patients were scanned using a 1.5-T scanner (Magnetom Avanto, Siemens Medical Systems, 
Erlangen, Germany) capable of echo-planar imaging. A circular-polarized head coil was used, 
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and the patient’s head was carefully secured with foam rubber pads to minimize head motion. 
Anatomic high-resolution images were acquired using a T1-weighted three-dimensional 
magnetization-prepared rapid acquisition gradient echo (3D-MPRAGE) sequence with the 
following parameters: repetition time (TR) = 1980 ms, echo time (TE) = 3.93 ms, flip angle = 15°, 
slice thickness = 1.0 mm, field of view (FOV) = 256 mm, matrix size = 256 × 256, pixel size = 1.0 
mm × 1.0 mm. Functional imaging was conducted using a T2*-weighted gradient echo-planar 
imaging sequence sensitive to blood-oxygen-level-dependent (BOLD) contrast. The imaging 
parameters were as follows: TR = 3000 ms, TE = 50 ms, flip angle = 90°, slice thickness = 3 mm, 
interslice gap = 1 mm, FOV = 256 mm, matrix size = 64 × 64, pixel size = 3.0 mm × 3.0 mm. 
Functional images were acquired in an oblique axial orientation aligned according to the 
anterior-posterior commissural (AC-PC) line. T2-weighted FLAIR images were also acquired to 
exclude subjects with significant vascular pathology. The T1-weighted and FLAIR images were 
evaluated by an experienced neuroradiologist. 
4.2.4 Structural MRI data analysis (studies II-III) 
Hippocampal volumetry was performed by a single investigator who was blinded to the clinical 
data who manually outlined the structure in an anterior to posterior-direction on the high-
resolution T1-weighted anatomic images according to previously published methods (Soininen 
et al. 1994, Insausti et al. 1998, Juottonen et al. 1998, Pennanen et al. 2004). Analyze 6.0 
(AnalyzeDirect, Inc, Overland Park, KS) was used to calculate the hippocampal volumes, which 
were then normalized to the whole-brain volume [(hippocampus volume / intracranial area) × 
100]. 
The whole-brain volume was calculated as the sum of white and grey matter volumes, which 
were obtained using tools in the VBM5-toolbox (Structural Brain Mapping Group, Department 
of Psychiatry, University of Jena; http://dbm.neuro.uni-jena.de/vbm) in SPM5 (Wellcome 
Department of Imaging Neuroscience, London, UK; www.fil.ion.ucl.ac.uk/spm). The origin of 
the spatial coordinates in individual T1-weighted images was set to the anterior commissure 
and images were reoriented perpendicular to the AC-PC line. Tools in the VBM5-toolbox were 
used to first segment the images into grey matter, white matter, and cerebrospinal fluid using a 
Hidden Markov Random Field model and then to estimate the corresponding volumes. Each 
patient was scanned three times; all structural results represent the mean of the three 
measurements (baseline, 1 week after baseline and 5 weeks after baseline). 
4.2.5 Functional MRI data analysis (studies II-III) 
Image preprocessing and data analysis were performed using SPM5. First, all functional 
volumes were spatially realigned and motion-corrected. Functional volumes were coregistered 
to T1-weighted structural volumes oriented along the AC-PC line. The coregistration success 
was visually controlled for each patient. Normalization parameters determined from the 
structural volumes were used to spatially normalize each functional volume to a standard 
template based on the Montreal Neurological Institute reference brain. Spatial smoothing was 
performed with an 8-mm Gaussian filter. Functional echo-planar imaging volumes were sorted 
into CUE, S1, X, and S2 conditions, and a contrast of the main effect of S2 was defined for each 
patient to investigate the activation responses related to face recognition. These conditions were 
modeled as blocks. Movement regressors were included into the first-level design matrix to 
improve statistical significance. A canonical hemodynamic response function was used to 
model BOLD responses.  
In the second publication, group-level fMRI data analysis was conducted using the general 
linear model on a voxel-by-voxel basis. SPM5 random-effects analysis was performed with one-
sample t-tests for within-group and paired-sample t-tests for between-group analyses, because 
the same patients were studied in all three experiments in this study. To investigate the 
relationship between the MMSE score and the BOLD fMRI signal, MMSE scores were used as 
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covariates of interest across all subjects' fMRI data, including age and sex as nuisance variables. 
fMRI data was thresholded using the following criteria: height threshold uncorrected p < 0.01, 
extent threshold > 100 voxels, threshold for reporting final statistical significance p < 0.05, 
cluster-corrected. Finally, region-of-interest (ROI) analyses to assess the mean percent signal 
change for the face recognition (S2) condition in the prefrontal cortices were performed using 
MarsBar 0.41 (Centre IRMf, CHU La Timone, Marseille, France). The ROIs were functionally 
defined such that the voxels which were significantly activated using the criteria of p < 0.05, 
cluster-corrected in the S2 condition, and located in the MarsBar anatomic areas of interest, 
were included in each ROI. The functional ROI measures were used to investigate the 
relationship between the baseline MMSE score and fMRI signal intensity.  
In the third publication, a group-level fMRI data analysis was conducted using one-sample t-
tests for within-group and paired-sample t-tests for between-group analyses as the same 
patients were studied in all three experiments. To investigate the relationship between the 
clinical response expressed as the MMSE change from baseline to 12 months’ follow-up and the 
fMRI activation difference between placebo and treatment, MMSE change from baseline to 12 
months’ follow-up was used as a covariate of interest across all subjects' fMRI data including 
age, gender and baseline MMSE score as nuisance variables. fMRI data was thresholded using 
the following criteria: height threshold uncorrected p < 0.01, extent threshold > 100 voxels, 
threshold for reporting final statistical significance p < 0.05, cluster-corrected. Finally, region-of-
interest (ROI) analyses to assess the mean percentage of the signal change for the face 
recognition (S2) condition in the left and right fusiform gyri were performed with MarsBar 0.41 
(Centre IRMf, CHU La Timone, Marseille, France) using the ROIs of MarsBar.  
4.2.6 Statistical data analysis (studies II-III) 
Statistical analysis of demographic, neuropsychologic, and volumetric MRI data, and fMRI 
behavioral and ROI data was conducted with SPSS 15.0 software (SPSS Inc, Chicago, IL) using 
the nonparametric Mann-Whitney U test and Wilcoxon, Spearman’s rank correlation and Linear 
regression. The level of statistical significance was set at two-tailed p < 0.05. 
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5 RESULTS 
5.1 DEMOGRAPHIC, COGNITIVE AND fMRI BEHAVIORAL CHARACTERISTICS 
OF THE SUBJECTS (STUDY I) 
As expected, the OCs, MCI subjects and AD patients differed in several demographic, cognitive 
and behavioral variables (Table 2; Anova and Mann-Whitney U-test): AD patients had higher 
trail making A and C test values than OCs. They also had lower MMSE and word list delayed 
recall and savings percentages than OCs and MCI subjects. The MCI subjects had higher CDR-
SB and trail making A and C test scores as well as lower MMSE, Boston naming and word list 
delayed recall and savings percentages than OCs. According to anova, there was a significant 
difference between the study groups in task performance with respect to the recognition of false 
alarms (P = 0.016).  
5.1.1 Structural MRI results  
The mean normalized right and left entorhinal cortical volumes (Table 6) were significantly 
different in all three study groups (anova and Mann-Whitney U-test): OC vs. MCI subjects, 
right and left, P < 0.0001; OCs vs. AD patients, right and left, P < 0.0001; and MCI subjects vs. 
AD patients, right and left, P < 0.0001. In contrast, hippocampal volumes were different only in 
AD patients relative to OCs (right and left, P < 0.0001) and MCI subjects (right, P = 0.01; left, P = 
0.02), but no difference was detected between MCI subjects and OCs (right, P = 0.5; left, P = 0.3).  
Table 6. The mean normalized volumes of the medial temporal lobe structures 
 Older controls MCI subjects         AD patients          ANOVA 
n Mean ± SD 
(range) 
N Mean ± SD  
(range) 
n Mean ± SD  
(range) 
P-value 
(F-value) 
Right entorhinal 
cortex 
21 7.28 ± 0.84   
(5.34 - 8.59) 
17 5.66 ± 0.85* 
(3.88 - 6.95) 
16 4.36 ± 0.61*# 
(3.17 - 5.28) 
< 0.00001 
(64.416) 
Left entorhinal 
cortex 
21 7.27 ± 0.81   
(5.34 - 8.72) 
17 5.47± 0.83*  
(3.68 - 7.01) 
16 4.43 ± 0.69*# 
(3.28 - 6.12) 
< 0.00001 
(62.696) 
Right 
hippocampus 
21 14.66± 2.03 
(12.25 - 20.16) 
17 14.09 ± 2.06 
(10.87 - 18.01) 
15 11.33 ± 2.15*# 
(6.93 - 14.93) 
0.00005 
(12.224) 
Left 
hippocampus 
21  13.86 ± 1.88 
(11.46 - 19.38) 
17 13.06± 2.40   
(8.35 - 17.05) 
15 10.44 ± 1.74*# 
(7.02 - 14.28) 
0.00003 
(13.013) 
Intracranial area 21 13896.3 ± 1088.7 
(12497-16242) 
17 13429.9 ± 975.8 
(12264-15455) 
16 13497.4 ± 1009.7 
(12264-16242) 
0.306 
(1.212) 
Significant difference (p < 0.05) between study groups (Mann-Whitney U-test): *vs. Older controls; #vs. MCI 
subjects. 
Table 7. Voxel-based morphometric analysis of medial temporal and posteromedial cortical regions 
between the study groups. 
Brain region Peak MNI Peak T Peak p Cluster size (voxels) 
Differential grey matter content between the study groups 
Older controls vs. MCI subjects 
    Right hippocampus 32,-16,-12 4.39 0.00005 3735 
    Left precuneus -20,-45,12 4.09 0.0001 746 
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    Right precuneus 17,-34,10 3.75 0.0003 2119 
    Left hippocampus -33,-11,-17 3.45 0.001 1998 
Older controls vs. AD patients 
    Left hippocampus -36,-26,-10 4.51 0.00003 9184 
    Right hippocampus 37,-23,-12 4.27 0.00007 5766 
    Right precuneus 7,-64,34 2.81 0.004 1244 
    Left precuneus -16,-67,30 2.41 0.001 1469 
MCI subjects vs. AD patients 
    Left precuneus -15,-63,32 4.79 0.00003 4790 
    Right precuneus 17,-63,29 3.37 0.001 326 
    Left posterior cingulate -2,-42,45 3.34 0.001 1515 
    Left hippocampus -32,-33,-7 3.11 0.002 1801 
Peak T-values, corresponding uncorrected p-values and MNI coordinates (x, y, z) are reported. Threshold for 
statistical significance p < 0.05, cluster-corrected. 
The statistically significant differences (P < 0.05, cluster-corrected) in brain atrophy between 
the study groups, as revealed by VBM, are presented in Figure 1 and Table 7. Within the MTL 
and posteromedial cortical ROIs examined in this study, the following differences were found 
between the groups: MCI subjects showed more atrophy than OCs in the bilateral anterior MTL, 
including the hippocampus and rhinal cortices, whereas there was no difference in the amount 
of posteromedial cortical atrophy between the OCs and MCI subjects (Figure 1). AD patients 
exhibited greater atrophy in the posterior MTL, including both the hippocampus and 
parahippocampal cortex, and in the bilateral posterior cingulate and precuneal cortices than 
MCI subjects (Figure 1A). As compared with OCs, AD patients displayed more widespread 
bilateral MTL and posteromedial cortical atrophy (Figure 1B; see Table 7 for the extent of 
atrophy clusters). 
5.1.2 Functional MRI results within groups  
During the fMRI word list learning paradigm, in the EN1 > EN2 comparison, OCs presented 
significant bilateral hippocampal activation (Table 8), whereas MCI subjects and AD patients 
exhibited smaller unilateral areas of activation located in the middle-posterior MTL regions. No 
statistically significant positive BOLD fMRI activation responses were found within the 
posterior midline cortical ROI in the EN1 > EN2 comparison.  
Within the group of OCs in the FIX > (EN1 + EN2) comparison, a large bilateral 
posteromedial region encompassing both posterior cingulate and precuneal cortices displayed 
significant fMRI task-induced deactivation responses (Table 8, Figure 2). In MCI subjects, there 
was a restricted area of deactivation in the borderline between the left posterior cingulum and 
precuneus (designated in the tables as ‘posterior cingulate⁄precuneal cortex’). AD patients 
showed deactivation only in a small area of the left posterior precuneus. No statistically 
significant MTL deactivation responses were observed in any of the groups.  
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Figure 1. (A) AD patients, when compared with MCI subjects, showed greater atrophy, as revealed 
by VBM (P<0.05, cluster-corrected), in the posterior MTL, including both the hippocampus and 
parahippocampal cortices and in the bilateral posterior cingulate and precuneal cortices (MNI 
coordinate of the crosshair located in the left posterior cingulum: -14,-61,32). (B) In comparison 
with OCs, AD patients showed widespread bilateral MTL and posteromedial cortical atrophy (MNI 
coordinate of the crosshair located in the left posterior cingulum: -13,-61,35). There was no 
difference detected in the extent of posteromedial cortical atrophy between the OC and MCI groups. 
Color bars depict the corresponding t-values. Right in the brain is right in the figure. 
Table 8. Areas of significant medial temporal activation and posteromedial cortical deactivation 
within and differential deactivation between the study groups. 
Brain region Peak MNI Peak T Peak p Cluster size (voxels) 
Areas of activation within the study groups 
    Older controls 
        Right hippocampus 26,-8,-15 5.05 0.0001 163 
        Left parahippocampal -22,-36,-15 3.97 0.0008 661 
    MCI subjects 
        Left parahippocampal -24,-26,-24 5.82 0.0001 101 
    AD patients     
        Right hippocampus 12,-36,6 3.55 0.001 119 
Areas of deactivation within the study groups 
    Older controls 
        Right posterior cingulate / precuneal cortex 4, -58, 36 6.12 0.0001 1367 
        Left posterior cingulate / precuneal cortex  -10, -54, 36 4.17 0.0002 -“- 
    MCI subjects 
        Left posterior cingulate / precuneal cortex -4, -54, 39 4.72 0.0001 349 
    Alzheimer patients 
        Left precuneal cortex -6, -68, 33 4.27 0.0003 220 
Differential deactivation between the study groups 
    ANOVA 
        Left precuneal cortex -2, -62, 36 2.56 0.007 20375 
        Right middle cingulate cortex 8, 18, 36 4.41 0.00003 161 
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    Older controls vs. MCI subjects 
        Left posterior cingulate / precuneal cortex -10, -66, 30 2.49 0.009 155 
    Older controls vs. AD patients 
        Left posterior cingulate / precuneal cortex -6, -48, 12 3.42 0.001 974 
        Right posterior cingulate / precuneal cortex 4, -54, 27 3.09 0.002 -“- 
Peak T-values, corresponding uncorrected p-values and MNI coordinates (x, y, z) are reported. Threshold for 
statistical significance p < 0.05, cluster-corrected. 
Figure 2. (A) MCI subjects showed significantly impaired fMRI task-induced deactivation responses 
in the left posterior cingulate⁄precuneal cortex as compared with OCs (MNI coordinate of the 
crosshair located in the left posterior cingulum: 8,-66,33). (B) AD patients showed less deactivation 
than OCs bilaterally in the posterior cingulate and precuneal cortices (MNI coordinate of the 
crosshair located in the posterior cingulum: 0,-54,24). Color bars depict the corresponding t-values. 
Right in the brain is right in the figure. 
5.1.3 Functional MRI results between groups  
The differences in fMRI task-induced deactivation between the study groups are presented in 
Table 8 and Figure 2. First, Anova was used to investigate differences in the fMRI deactivation 
pattern across the study groups. In these subject groups, anova revealed significantly different 
fMRI task-induced deactivation bilaterally in the posteromedial cortices.  
OCs showed more deactivation in the borderline between the left posterior cingulate and 
precuneal cortices than MCI subjects. In comparison with AD patients, OCs showed 
significantly greater deactivation both in the right and left posterior cingulate as well as in the 
precuneal cortices. No differences were observed in posteromedial cortical function between the 
MCI subjects and AD patients nor were any statistically significant differences detected in the 
extent of MTL activation between the study groups in the spm2 random-effects analyses 
exceeding the extent threshold of > 100 voxels and using a cluster-corrected P < 0.05 as a final 
statistical threshold for significance. However, as a subthreshold finding, OCs exhibited more 
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activation than AD patients in the right hippocampus (MNI 28, 0, 15; peak P = 0.01; peak t = 
2.07; cluster size, 17 voxels). 
5.1.4 Correlations between structural and functional MRI findings across the study groups  
In spm2 correlational analyses across all study subjects, significant negative correlations were 
found between the MTL volumes and posteromedial cortical fMRI deactivation response 
pattern (Table 9; Figure 3A) (with age and gender as nuisance variables). The anatomical areas 
demonstrating the most significant negative correlations with the entorhinal volumes were 
predominantly observed in the retrosplenial cortex (Figure 3A), whereas areas correlating with 
the hippocampal volumes were predominantly found in the posterior cingulum (Figure 3B). 
There was also an area in the left posterior precuneus that correlated positively with entorhinal 
volumes. No significant correlations were observed between entorhinal or hippocampal 
volumes and MTL fMRI responses. Correlation analyses were also performed with native (i.e. 
not-normalized) volumes, but they gave essentially identical results – there was no significant 
difference between correlations calculated with normalized and not-normalized entorhinal and 
hippocampal volumes.  
Table 9. Posterior midline cortical deactivation areas demonstrating significant correlation with 
entorhinal and hippocampal volumes across all study subjects.  
Brain region Peak MNI Peak T Peak p Cluster size (voxels) 
Entorhinal cortex 
    Areas of negative correlation with right entorhinal volume 
        Right posterior cingulate / retrosplenial cortex 20,-46,0 2.88 0.003 207 
        Left posterior cingulate / retrosplenial cortex -24,-46,0 2.83 0.003 142 
    Areas of negative correlation with left entorhinal volume 
        Right posterior cingulate / retrosplenial cortex 20,-46,0 3.30 0.001 109 
        Left posterior cingulate / retrosplenial cortex -16,-50,9 2.58 0.005 144 
    Areas of positive correlation with left entorhinal volume 
        Left precuneal cortex -8, -66, 42 3.51 0.0005 189 
Hippocampus 
    Areas of negative correlation with right hippocampal volume 
        Right posterior cingulate / retrosplenial cortex 20,-48,6 3.89 0.0002 910 
        Left posterior cingulate / retrosplenial cortex -15,-48,5 3.35 0.001 -“- 
    Areas of negative correlation with left hippocampal volume 
        Right posterior cingulate / retrosplenial cortex 20,-48,6 3.34 0.001 122 
        Left posterior cingulate / retrosplenial cortex -16,-48,6 2.52 0.007 124 
Peak T-values, corresponding uncorrected p-values and MNI coordinates (x, y, z) are reported. Threshold for 
statistical significance p < 0.05, cluster-corrected.  
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Figure 3. Brain areas demonstrating decreased fMRI task-induced deactivation along with greater 
entorhinal (A) and hippocampal (B) atrophy when the mean of right and left entorhinal and 
hippocampal volumes was used as a covariate of interest in the spm2 analyses. MNI coordinates of 
the crosshairs were 8,-48,12 in the right retrosplenial cortex (A) and 0,-50,24 in the posterior 
cingulum (B). Color bars depict the corresponding t-values. Right in the brain is right in the figure.  
5.2 CLINICAL CHARACTERISTICS OF STUDY SUBJECTS (STUDIES II-III) 
The demographic and cognitive details of the subjects in study 2 are presented in Table 3 and in 
study 3 in Table 4.  
Behavioral measures gathered during the fMRI task were designed to measure patient 
cooperation and attention. The results of the behavioral measurements are shown in Table 10. 
There were no statistically significant differences between the behavioral measurements in the 
placebo, acute, and chronic treatment conditions. The clinical characteristics at baseline and at 
the 6 and 12 months’ follow-up are presented in detail in table 4. 
Table 10. Behavioral results during task performance with placebo, acute and chronic ChEI 
treatments. 
 
Placebo Acute  Chronic    
Mean ± SD Mean ± SD  Mean ± SD 
Encoding  reaction time, ms 1027.2 ± 527.8 1049.4 ± 640.6 1075.5 ± 598.3 
Recognition hits % 21.0 ± 8.6 22.0 ± 7.4 20.3 ± 10.0 
Recognition false alarms % 3.5 ± 4.5 3.3 ± 3.7 2.3 ± 2.7 
There were no significant differences (p < 0.05) (Wilcoxon, two related samples t-test) between placebo, acute 
and chronic treatment imaging sessions. 
The average MMSE scores remained stable at both the 6 and 12 months’ follow-ups when 
compared to baseline. Eight patients improved their MMSE score at 6 months and nine patients 
at 12 months’ follow-up. The MMSE scores declined for three patients at 6 months and for two 
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patients at 12 months by more than 4 points. The mean CERAD scores for verbal fluency had 
significantly declined from the baseline values compared to those detected at the 6 months’ and 
12 months’ follow-ups. Instead CERAD word list learning scores significantly improved at the 
12 months’ follow-up when compared to baseline, and CERAD Word List delayed savings (%) 
and CERAD copying delayed savings (%) significantly improved at the 6 months’ follow-up 
when compared to baseline. Years of education correlated significantly with MMSE difference 
between baseline and the 12 months’ follow-up (r = 0.477, p = 0.045). No significant correlations 
were found between age, gender, or volumetry and MMSE difference.  
5.2.1 fMRI Results During Placebo, and Acute and Chronic ChEI Treatment Conditions 
(study2) 
In the placebo condition, while performing the face recognition task (S2), the AD patients 
displayed significant activation (Table 11, Figure 4A) in the left hippocampus and in the 
bilateral fusiform, left middle cingulate, right precuneal, bilateral prefrontal, and left calcarine 
cortices, as well as in the right thalamus.  
During the acute exposure to rivastigmine when performing the face recognition task, the 
patients displayed significant activation (Table 11, Figure 4B) in the left fusiform, right superior 
temporal, bilateral middle temporal, right anterior cingulate, right precuneal, bilateral 
prefrontal, and left calcarine cortices, as well as in the left putamen and bilateral thalamus.  
In the chronic medication condition, bilateral fusiform, bilateral middle temporal, prefrontal 
and calcarine cortices, as well as the left thalamus were significantly activated during the face 
recognition memory task (Table 11, Figure 4C). Cerebellar activation was invariably present in 
the placebo, acute and chronic treatment conditions.  
Table 11. Brain areas of significant fMRI activation with placebo, acute and chronic treatments and 
differential activation between the placebo, acute and chronic treatments. 
Brain region Peak MNI (x,y,z) Peak T Peak p Voxel count 
Areas of activation within study groups 
Placebo 
    L middle cingulate cortex -3,-8,48 7.55 0.000001 2557 
    L superior frontal gyrus -24,-6,46 7.27 0.000001 7126 
    L / R fusiform gyrus -47,-59,-22 / 39,-60,-
22  
6.16 / 
7.24 
0.000006 / 
0.000001 
2782 / 4182 
    L / R postcentral gyrus -62,-21,24 / 41,-24,46 4.68 / 
5.94 
0.0002 / 
0.00001 
145 / 1528 
    L hippocampus -20,-15,-12 5.32 0.00004 132 
    R precentral gyrus 51,8,46 4.87 0.0001 790 
    L middle frontal gyrus -38,42,28 4.45 0.0003 310 
    R precuneus 17,-45,40 4.25 0.0004 158 
    R rolandic operculum 56,5,14 4.25 0.0004 384 
    L calcarine gyrus -17,-71,6 4.10 0.0006 179 
    R thalamus 15,-11,6 3.83 0.001 118 
Acute     
    R / L inferior frontal  
    Gyrus 
50,17,28 / -48,35,24 7.59 / 
4.29 
0.000001 / 
0.0004 
4205 / 932 
    L supplemental motor area -5,15,44 7.33 0.000001 4567 
    L / R rolandic operculum -51,6,2 / 54,-12,20 7.25 / 
5.45 
0.000001  / 
0.00003 
8610 / 3335 
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    L fusiform gyrus -23,-54,-16 6.78 0.000002 7454 
    L / R thalamus -9,-18,6 / 15,-18,10 6.04 / 
4.02 
0.000008 / 
0.0007 
596 / 362 
    L middle temporal gyrus -45,-53,6 5.53 0.00003 596 
    R precuneus 3,-65,52 4.42 0.0003 105 
    L putamen -30,-17,2 4.33 0.0004 163 
    R anterior cingulate      
    Cortex 
14,36,14 4.19 0.0005 169 
    R superior parietal lobule 33,-69,50 4.18 0.0005 107 
    R amygdale 24,2,-12 4.16 0.0005 185 
    R parahippocampal gyrus 30,0,-30 4.11 0.0006 185 
    L inferior occipital gyrus -36,-84,-6 3.92 0.0009 460 
    R superior temporal gyrus 44,-35,16 3.84 0.001 188 
    L calcarine gyrus -11,-75,5 3.83 0.001 122 
    R middle temporal gyrus 66,-39,0 3.60 0.001 290 
Chronic  
    L supplemental motor area -6,-15,48 11.53 0.0000001 24597 
    L inferior parietal lobule -44,-30,42 8.66 0.0000001 17069 
    R fusiform gyrus 38,-60,-22 6.12 0.000007 3852 
    L / R middle temporal     
    Gyrus 
-53,-57,8 / 51,-71,16 5.26 / 
4.14 
0.00005 / 
0.0005 
3883 / 118 
    L thalamus -12,-15,0 4.74 0.0001 443 
    L calcarine gyrus -24,-72,6 4.36 0.0003 159 
    R insula lobe 32,-20,12 4.18 0.0005 119 
    R inferior occipital gyrus 24,-95,-4 3.61 0.001 214 
    R middle frontal gyrus 39,48,6 3.56 0.001 148 
    R calcarine gyrus 11,-75,12 3.40 0.001 214 
Differential activation between study groups 
Acute > Placebo 
R superior temporal gyrus 45,-32,14 3.91 0.0009 196 
R / L inferior frontal gyrus 48,26,28 / -53,12,0 3.53 / 
3.70 
0.001 / 
0.001 
172 / 150 
R middle temporal gyrus 65,-38,-2 3.28 0.002 210 
Chronic>Placebo 
L middle temporal gyrus -51,-57,6 4.84 0.0001 166 
L precentral gyrus -47,-3,34 4.36 0.0003 306 
R inferior frontal gyrus 47,33,26 4.24 0.0004 327 
R rolandic operculum 57,-8,16 4.05 0.0007 101 
L inferior parietal lobule -51,-41,40 3.80 0.001 147 
L temporal pole -41,11,-28 3.79 0.001 139 
L anterior cingulate cortex -6,32,14 3.77 0.001 462 
L putamen -21,6,6 3.74 0.001 115 
R postcentral gyrus 53,-12,38 3.70 0.001 172 
L superior frontal gyrus -20,54,22 3.65 0.001 135 
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R superior medial gyrus 9,54,28 3.63 0.001 123 
R superior occipital gyrus 21,-71,18 3.47 0.001 111 
R caudate nucleus 11,14,14 3.46 0.001 349 
L middle frontal gyrus -38,26,36 3.31 0.002 155 
Chronic>Acute 
L precuneus -11, -57, 50 6.26 0.000003 427 
L precentral gyrus -35, -2, 44 3.83 0.001 108 
L supramarginal gyrus -45, -24, 34 3.48 0.001 111 
R superior frontal gyrus 21, 50, 20  3.43 0.001 114 
L anterior cingulate -8, 30, 24 3.15 0.002 104 
L middle frontal gyrus -42,17,44 3.26 0.002 117 
Peak T-values, corresponding uncorrected p-values and MNI coordinates (x, y, z) are reported. Threshold for 
statistical significance p < 0.05, cluster-corrected. L = left; R = right. 
5.2.2 Differences in fMRI Activation between Placebo, and Acute and Chronic ChEI 
Treatment Conditions (study 2) 
Differences in the whole-brain fMRI activation patterns between the placebo, acute, and chronic 
conditions are presented in Table 11 and Figure 5). When the patients received acute treatment, 
the right middle and superior temporal and bilateral prefrontal cortices displayed more 
activation than when the patients received placebo (p < 0.05, cluster-corrected, paired t-test).  
After 1 month of chronic ChEI treatment, the patients showed greater activation in the left 
middle temporal, left anterior cingulate, bilateral prefrontal, and left parietal areas than when 
receiving placebo (p < 0.05, cluster-corrected, paired t-test). Patients receiving the chronic 
treatment showed more activation in bilateral prefrontal, left middle frontal, left precuneal, and 
left anterior cingulate areas than had been present while they were acutely treated. Patients 
receiving the placebo exhibited no areas of significantly increased fMRI activity compared to 
the acute or chronic treatment conditions.  
5.2.3 Correlations between cognition and differential fMRI activity during  Chronic vs 
Placebo treatment (study2) 
 
In the investigation of the relationship between the baseline MMSE score and the difference in 
BOLD fMRI signal intensity between placebo and chronic treatment conditions at the map level, 
the MMSE scores were used as covariates of interest across all subjects' fMRI data, including 
age and sex as nuisance variables. There was a significant negative correlation between the 
MMSE score and the BOLD signals in the right prefrontal and posteromedial cortices, and also 
in the left prefrontal, bilateral cingulate, bilateral temporal, right precuneus, bilateral parietal 
and bilateral occipital cortices Figure 5C, Table 12. The MMSE scores of individual patients are 
shown in table 5. 
The association between all 20 patients’ fMRI signal intensities within the prefrontal ROI and 
baseline MMSE scores was studied using Spearman’s correlation analysis. A greater increase in 
prefrontal fMRI signal magnitude while on chronic ChEI versus placebo correlated significantly 
with the MMSE score (left prefrontal cortex: r = -0.545, p = 0.013; right prefrontal cortex: r = -
0.366, p = 0.012). In other words, a greater increase in the prefrontal activity during chronic 
treatment compared to placebo correlated with poorer baseline cognition in terms of the MMSE 
score according to both the fMRI map level and ROI data analysis approaches.  
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Figure 4. Patients with Alzheimer’s disease demonstrated significant fMRI activation responses in 
several brain areas during the face recognition memory task during A) placebo, B) acute and C) 
chronic medication conditions (MNI coordinate of the crosshair: 56,11,36). Color bar represents the 
corresponding T-values. The image is shown according to neurological convention (that is, left in the 
figure is left in the brain) at a threshold of p<0.05, cluster-corrected. 
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Figure 5. Patients with Alzheimer’s disease demonstrated significantly higher functional MRI 
activation during A) acute (MNI coordinate of the crosshair: 48,23,28) and B) chronic (MNI 
coordinate of the crosshair: 47,32,24) cholinergic medication compared to placebo. C) Difference in 
fMRI activation between placebo and chronic treatment was statistically significantly negatively 
correlated with the baseline MMSE score especially in the right prefrontal and posteromedial 
cortices. Color bar represents the corresponding T-values. The image is shown according to 
neurological convention at a threshold of p<0.05, cluster-corrected. 
Table 12. Brain areas where there was a significant negative correlation between fMRI activation 
difference between placebo and chronic treatment and MMSE. No areas were found where there 
were statistically significant positive correlations between these parameters. 
Brain region Peak MNI (x,y,z) Peak T Peak p Voxel count 
Areas of activation within study groups 
L / R inferior parietal lobule -54,-41,36 / 38,-39,44 7.37 / 
3.44 
0.0000001 / 
0.001 
6051 / 106 
L / R middle frontal gyrus -45,15,38 / 38,-8,52 4.91 / 
5.29 
0.00005 / 
0.00002 
279 / 1261 
L middle temporal gyrus -47,-47,8 4.82 0.00006 350 
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R middle cingulate cortex 11,-18,36 4.71 0.00008 518 
Right precuneus 6,-51,50 4.67 0.00008 221 
L / R superior temporal gyrus -41,-39,20 / 53,-39,18 4.51/4.07 0.0001 / 
0.000 
421 / 212 
Right cuneus 17,-98,12 4.49 0.0001 237 
Left postcentral gyrus -44,-11,42 4.39 0.0002 194 
R inferior frontal gyrus 45,35,24 4.30 0.0002 192 
R superior frontal gyrus 15,44,34 3.97 0.0004 683 
R supramarginal gyrus 53,-38,34 3.80 0.001 239 
L precentral gyrus -30,-2,44 3.72 0.001 133 
L superior occipital gyrus -14,-98,16 3.50 0.001 171 
L anterior cingulate cortex -8,17,30 3.44 0.001 132 
L fusiform gyrus -29,-50,-12 3.39 0.002 204 
R superior parietal lobule 27,-63,52 3.14 0.003 102 
Peak T-values, corresponding uncorrected p-values and MNI coordinates (x, y, z) are reported. Threshold for 
statistical significance p < 0.05, cluster-corrected. L = left; R = right. 
5.2.4 Correlation analysis of MMSE change in 12 months’ follow-up and fMRI results (study 
3) 
It was decided to calculate the correlation between clinical response, expressed as the MMSE 
change from baseline to 12 months’ follow-up and the initial fMRI activation difference between 
placebo and acute treatment (figure 6, Table 13). The positive correlation was most evident 
(greatest voxel extent) in the right prefrontal cortex but was also present in the right temporal 
area, right cingulated cortex and left prefrontal cortex, indicating that the increased activation in 
these areas, which had been induced by cholinergic stimulation, was associated with improved 
performance in the MMSE test. A negative correlation was most evident (greatest voxel extent) 
in the left prefrontal cortex and left fusiform gyrus, but was also found in the left precuneus, 
bilateral temporal areas, left hippocampus, right fusiform gyrus and left occipital area. 
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Figure 6. fMRI activation difference in Alzheimer’s disease patients A) between placebo and acute 
treatment was significantly positively correlated with MMSE score difference between baseline and 
12 months’ follow-up, especially in the right prefrontal cortex. B) Significant negative correlation 
was found in the left prefrontal cortex and cingulum. The color bar represents the corresponding T-
values. The image is shown according to the neurological convention at a threshold of p<0.01 and 
100 contiguous voxels for display purposes. 
Table 13. Brain areas in which the fMRI activation difference between placebo and acute treatment 
correlated with the MMSE difference between baseline and 12 months’ follow-up. 
Brain region Peak MNI (x,y,z) Peak T Peak p 
(uncorrecte
d) 
Voxel 
extent 
Difference between placebo and acute treatment was correlated with MMSE difference 
between baseline and the 12 months’ follow-up 
Positive correlation 
Right superior temporal gyrus 53,-12,-6 7.15 0.000002 463 
Right precentral gyrus 51,11,34 6.80 0.000003 4027 
Left SMA -9,11,46 6.50 0.000005 304 
Left inferior frontal gyrus -42,26,26 5.28 0.00006 375 
Right middle cingulate cortex 11,3,34 5.18 0.00008 233 
Negative correlation 
Left inferior frontal gyrus -57,20,16 7.69 0.000001 503 
Left middle occipital gyrus -32,-77,4 6.90 0.000003 517 
Left fusiform gyrus -42,-66,-20 6.79 0.000003 865 
Right fusiform gyrus 29,-33,-24 6.71 0.000004 254 
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Left superior temporal gyrus -56,-35,22 6.53 0.000005 670 
Left precuneus -8,-41,4 6.28 0.000008 607 
Left hippocampus -33,-18,-18 5.91 0.00002 422 
Right middle temporal gyrus 57,-32,-2 5.18 0.00008 702 
Threshold for statistical significance p < 0.05, cluster-corrected. 
Correspondingly, the correlation was studied between MMSE change between baseline and 
12 months’ follow-up and fMRI activation difference between placebo and chronic treatment 
(figure 7, Table 14). A positive correlation was most evident (greatest voxel extent) in the right 
prefrontal cortex, and was also detected in left prefrontal cortex, right precuneus, left cingulate 
cortex, right parietal and right occipital cortex. A negative correlation was most evident 
(greatest voxel extent) in the left occipital cortex, but was also found in the left temporal area, 
left prefrontal cortex, right temporal area and left fusiform gyrus. 
Both placebo versus chronic and placebo versus acute analysis showed the most evident 
positive correlations in right prefrontal and most evident negative correlations in left fusiform 
and occipital area. In this study, the “face recognition” memory paradigm was used, which 
significantly activated fusiform gyri in placebo, acute and chronic treatment (table 11). Thus, 
further analysis concentrated on the fusiform gyri.  
 
Figure 7. fMRI activation difference in Alzheimer’s disease patients A) between placebo and chronic 
treatment was significantly positively correlated with MMSE score difference between baseline and 
12 months’ follow-up especially in the right prefrontal cortex. B) Significant negative correlation was 
found in the left prefrontal cortex and left cingulum. The color bar represents the corresponding T-
values. The image is shown according to neurological convention at a threshold of p<0.01 and 100 
contiguous voxels for display purposes. 
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Table 14. Brain areas in which the fMRI activation difference between placebo and chronic treatment 
correlated with the MMSE difference between baseline and 12 months’ follow-up. 
Brain region Peak MNI (x,y,z) Peak T Peak p 
(uncorrected) 
Voxel 
extent 
Difference between placebo and chronic treatment was correlated with MMSE difference 
between baseline and the 12 months’ follow-up 
Positive correlation 
Right precuneus 14,-59,46 7.59 0.000001 1321 
Left middle cingulate -8,-18,36 6.72 0.000004 829 
Right precentral gyrus 48,-3,40 6.10 0.00001 2086 
Right angular gyrus 53,-50,24 6.01 0.00001 340 
Right inferior frontal gyrus 41,17,32 5.86 0.00002 1223 
Left anterior cingulate cortex -11,39,10 5.49 0.00004 1334 
Left precentral gyrus -50,-3,50 5.03 0.0001 640 
Left inferior frontal gyrus -39,17,30 4.88 0.0001 373 
Right middle occipital gyrus 33,-84,12 4.70 0.0002 253 
Left supramarginal gyrus -62,-42,26 4.39 0.0004 201 
Right superior parietal lobule 21,-59,50 3.97 0.001 228 
Negative correlation 
Left middle occipital gyrus -18,-101,0 7.48 0.000001 873 
Left middle temporal gyrus -54,-47,4 6.12 0.00001 765 
Left lingual gyrus -12,-66,2 5.59 0.00003 267 
Left inferior frontal gyrus -39,9,22 5.32 0.00006 279 
Right inferior temporal gyrus 56,-51,-10 5.01 0.0001 311 
Left lingual gyrus -24,-56,-6 4.41 0.0004 212 
Left fusiform gyrus -41,-45,-20 3.82 0.001 213 
Peak T-values, corresponding uncorrected p-values and MNI coordinates (x, y, z) are reported. Threshold for 
statistical significance p < 0.05, cluster-corrected. 
The differences in the fMRI signal intensity between placebo and chronic treatment 
significantly negatively correlated with MMSE difference between baseline and 12 months’ 
follow-up in left fusiform gyri (r = - 0.693; p = 0.001) (Figure 8). In addition, the association 
between all 18 patients’ fMRI signal intensity differences between right and left fusiform gyri 
after chronic cholinergic treatment and the MMSE score difference between baseline and 6 / 12 
months follow-up was studied using Spearman’s correlation and linear regression analysis. The 
signal intensity difference between right and left fusiform gyri correlated significantly with the 
MMSE score difference (r = 0.584; p = 0.011 / r = 0.714; p = 0.001). According to the linear 
regression analysis, the model stated that 14.3/31.6 % of the variation in MMSE score difference 
could be explained by the fMRI signal intensity difference (R2 = 0.143; p = 0.122 / R2 = 0.316; p = 
0.015).  
In addition, the patients were divided into two groups: those who had higher signal intensity 
in right versus left fusiform gyri, and those who had higher signal intensity in left versus right 
fusiform gyri. The ChEI treatment responders were designated as those patients who had 
higher MMSE scores during 6 and 12 months’ follow-up than they had had at baseline (8 / 9 
patients), in contrast to the non-responders who were the individuals in whom the MMSE score 
remained stable or even declined (10 / 9 patients). A higher signal intensity in right versus left 
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fusiform gyrus predicted a response to ChEI treatment via an increase in the MMSE score at the 
6 / 12 months follow-up with 77.8 / 77.8 % sensitivity and 88.9 / 77.8 % specificity. 
 
Figure 8. MMSE difference between baseline and 12 months’ follow-up as a function of signal 
intensity difference between chronic and placebo treatment in right/left (A/B) fusiform gyri (r = - 
0.150; p = 0.553 / r = - 0.693; p = 0.001). MMSE = Mini-Mental State Examination. 
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6 DISCUSSION 
6.1 STRUCTURE AND FUNCTION OF MEDIAL TEMPORAL AND 
POSTEROMEDIAL CORTICES IN EARLY ALZHEIMER’S DISEASE (STUDY 1) 
This study demonstrates that both the structure of the entorhinal cortex and the function of the 
posteromedial cortices are significantly affected early in the course of AD and furthermore, that 
these structural and functional alterations are correlated with each other. In the spm2 map-level 
analyses, increasing amounts of entorhinal atrophy were related to increasing failure of fMRI 
task-induced deactivation responses in the posteromedial cortices while the subjects were 
performing the word list learning task. Statistically significant differences in the extent of 
structural atrophy of the posteromedial cortices were found in clinical AD patients in 
comparison with OCs and MCI subjects, but not between MCI subjects and OCs. In other 
words, functional brain alterations can be detected at a time when no structural changes are 
detectable within the posteromedial cortical region.  
There are some limitations to this study. In order to reveal both the MTL and posteromedial 
fMRI deactivation patterns, it was decided to compare simple visual fixation with active 
encoding of words. In addition to the cognitive difference, the motor demands between these 
conditions were also different, i.e. during encoding processing, the subjects were asked to press 
the response button once they had memorized the corresponding word, but there was no motor 
response required during the fixation baseline condition. The data analysis was, however, 
focused on the MTL and posteromedial ROIs, where effects of motor functions on brain activity 
are believed to be rather insignificant (Ashe et al. 1994, Mattay et al. 1999). Another factor 
possibly affecting the fMRI response pattern of the AD patients is the use of ChEIs. Ten of 16 
AD patients were on ChEIs, whereas, according to the general guidelines, none of the MCI or 
healthy elderly subjects were taking medication with potential effects on cognition. However, 
one would expect that the cholinergic medication would enhance cognition, attention in 
particular, and would thus be more likely to ‘normalize’ the fMRI activation pattern of the AD 
patients instead of accentuating differences between the study groups (Gu 2002, Kircher et al. 
2005, Shanks et al. 2007, Bentley et al. 2008). Furthermore, perhaps the most important between-
group comparison in this study is the one between OCs and MCI subjects, and none of the 
subjects of these groups were receiving cholinergic medication. Finally, in line with several 
previous structural MRI studies, it was decided to use normalized MTL volumes in the data 
analyses, which could have affected the results if the relationship between the studied 
parameters and the normalization factor had been significant. However, the data were also 
analyzed with non-normalized volumes, but this caused no change in the results.  
The main finding of this study was the strong relationship between the structural MRI 
measures of the entorhinal cortex and fMRI responses of the posteromedial cortices, or, more 
specifically, of responses in the retrosplenial and posterior cingulate cortices. These results 
showing significant entorhinal atrophy preceding hippocampal atrophy, very early in the 
course of AD, are consistent with previous reports (Killiany et al. 2000, Dickerson et al. 2001, 
Pennanen et al. 2004). Similarly, these results are supported by previous FDG-PET studies 
demonstrating posteromedial cortical hypometabolism (Minoshima et al. 1997, Nestor et al. 
2003) and by recent fMRI studies reporting reduced task-induced deactivation responses in 
both MCI subjects and AD patients relative to cognitively healthy elderly controls (Lustig et al. 
2003, Greicius et al. 2004, Rombouts et al. 2005, Pihlajamäki et al. 2009, Sperling et al. 2010). 
Most importantly, the present results in these elderly individuals, whose cognition ranged from 
intact to amnestic MCI and ultimately to clinical AD (in other words, spanning a spectrum from 
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practically no entorhinal atrophy to severely shrunken entorhinal cortices), are in agreement 
with the previous structure-function imaging studies in non-human primates and in post-
mortem AD patients (Meguro et al. 1999, Blaizot et al. 2002, Bradley et al. 2002). Together with 
the previous reports, the present study performed within the MRI modality supports the 
hypothesis that functional disruption of the posteromedial cortices reflects remote effects of the 
pathological changes occurring in the entorhinal cortex (Hyman et al. 1984, Braak et al. 1991, 
Gómez-Isla et al. 1996, Kordower et al. 2001). This is in agreement with the known strong 
anatomical connectivity between the entorhinal and posteromedial cortices (Lavenex et al, 2000, 
Kobayashi et al. 2003, Cavanna et al. 2006, Kobayashi et al. 2007), although, until now, there has 
been little in vivo evidence for a connection in humans. It is interesting to note that the brain 
area demonstrating the most significant relationship between functional alterations and 
entorhinal atrophy was predominantly located in the retrosplenial cortex – an area known to be 
directly and reciprocally connected with the entorhinal cortex (Kobayashi et al. 2003, Kobayashi 
et al. 2007, Jones et al. 2007).  
Another new finding in this (cross-sectional) study was that dysfunction of the 
posteromedial cortices could be observed even though no significant macroscopic atrophy was 
apparent in the same cortical areas. In previous structural MRI studies, there have been 
somewhat varying VBM findings regarding whether or not there is atrophy in the posterior 
cingulate and precuneal cortices in MCI, the criteria for which may well have varied between 
different research centers (Chételat et al. 2002, Karas et al. 2004, Pennanen et al. 2005, 
Hämäläinen et al. 2007b, Whitwell et al. 2008). The results of the present study also suggest that 
the anatomically distinct parts of the posteromedial cortices may not be equally affected by the 
AD disease process; instead the extreme posterior and superior parts of the precuneus may be 
relatively spared, even in clinical AD, in terms of both structure and function. In contrast, the 
retrosplenial and posterior cingulate cortices are likely to be some of the earliest brain regions 
demonstrating functional alterations in terms of abnormal FDG-PET metabolism or BOLD fMRI 
responses in the course of AD, even in subjects genetically at risk for AD (Minoshima et al. 1997, 
Reiman et al. 1998, Lustig et al. 2003, Nestor et al. 2003, Greicius et al. 2004, Rombouts et al. 
2005, Pihlajamäki et al. 2009, Sperling et al. 2010).  
Similar to the findings with posteromedial cortical atrophy, significant hippocampal atrophy 
was found only in clinical AD patients, and not in MCI and control subjects. This differed from 
the posteromedial cortical dysfunction and entorhinal atrophy observed in MCI subjects as 
compared with controls. This finding is in good agreement with previous functional studies 
reporting that reduced posteromedial cortical glucose metabolism and perfusion precede 
hippocampal atrophy and the decline in perfusion (Reiman et al. 1998, Kogure et al. 2000). 
However, the present study adds to the previous findings, in that although functional 
disruption of the posteromedial cortices was found prior to the detection of any significant 
hippocampal atrophy, it appears to parallel the emerging entorhinal atrophy. Longitudinal 
studies and trials in ‘pre-MCI’ are warranted to clarify whether alterations in posteromedial 
cortical function also precede the entorhinal atrophy and any clinically measurable deficits in 
episodic memory. There is evidence to suggest that posteromedial cortical dysfunction may be 
one of the earliest functional imaging markers of compromised memory performance in older 
aged subjects (Miller et al. 2008).  
In addition to remote pathophysiological effects of entorhinal pathology, such as 
neurofibrillary tangles and loss of neurons and synapses, another potential explanation for the 
disrupted posteromedial cortical function in AD has been provided by PET studies using a 
tracer for beta amyloid, [11C]Pittsburgh compound B (PIB) (Klunk et al. 2004). These PIB-PET 
studies have revealed that the posterior cingulum and precuneus are some of the earliest brain 
areas containing amyloid beta (Ab) plaques (Mintun et al. 2006, Forsberg et al. 2007), the other 
pathological hallmark of AD. To date, PIB-PET studies in cognitively impaired subjects have 
found no consistent relationship between the level of PIB uptake and measures of brain atrophy 
(Archer et al. 2006, Jack et al. 2008, Chételat et al. 2010, Villemagne et al. 2013) or with FDG-PET 
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measures of posteromedial cortical glucose metabolism (Edison et al. 2007; Engler et al. 2006), 
and neuropsychological measures of memory (Pike et al. 2007, Jack et al. 2008, Koivunen et al. 
2012) although new data on these important questions are accumulating continuously. The 
possibility that posteromedial cortical dysfunction, such as observed in the present study, 
would solely reflect local accumulation of fibrillar Ab remains to be investigated in future 
multimodal studies combining fMRI with PIB-PET imaging. Some evidence has emerged from 
work done in non-human primates with entorhinal cortical lesions but most likely without 
significant amounts of Ab pathology, that there is hypometabolism inposterior midline cortical 
regions (Meguro et al. 1999, Blaizot et al. 2002). This indicates that morphological alterations in 
the entorhinal cortex can lead to abnormal posteromedial cortical metabolism. This may well be 
the case in human MCI subjects and AD patients, even though this may be affected by the 
presence of local Ab accumulation.  
Although the relationship between Ab pathology and memory function in AD still remains 
to be clarified (Pike et al. 2007, Jack et al. 2008, Rowe et al. 2010), there is convincing data to 
support the crucial role of the entorhinal cortex and hippocampus in declarative memory 
formation (Leonard et al. 1995, Fernandez et al. 1999, Buckmaster et al. 2004) and also for the 
significant role of the MTL pathology contributing to the characteristic episodic memory 
impairment encountered in AD (Hyman et al. 1984, deToledo-Morrell et al. 2004). The role of 
the posteromedial cortices in cognition, and memory in particular, is less well understood. 
Functional imaging studies have pointed to a role of the posteromedial cortices in memory 
retrieval (Shannon et al. 2004, Vannini et al. 2011). For example, less activity has been reported 
within these cortical regions in MCI patients than in healthy elderly subjects during recognition 
and episodic retrieval (Johnson et al. 2006, Ries et al. 2006). Studies in healthy young and older 
subjects have indicated that the greater fMRI task-induced deactivation in the posteromedial 
regions during encoding is related to better subsequent memory performance (Daselaar et al. 
2004, Grady et al. 2006, Miller et al. 2008, Vannini et al. 2011). Recently, evidence has emerged 
that in cognitively intact older individuals, the intrinsic connectivity between the hippocampus 
and posteromedial cortices was significantly related to episodic memory (but not with non-
memory) performance (Wang et al. 2010). One could speculate that a failure of memory 
encoding as a result of MTL pathology in MCI and AD, could be related to impaired regulation 
of neural activity in these strongly interconnected posteromedial cortices, and that these are 
deactivated in cognitively intact elderly individuals but this deactivation does not occur in MCI 
and AD subjects (Lustig et al. 2003, Greicius et al. 2004, Rombouts et al. 2005, Petrella et al. 
2007a, Petrella et al. 2007b, Pihlajamäki et al. 2009). When viewed in the light of previous 
reports, this study emphasizes the early involvement of both MTL and posteromedial cortical 
function during the course of AD, and highlights that an intact connection between these 
regions is important for both memory encoding and retrieval. It is noteworthy that in fMRI, the 
terms ‘activation’ and ‘deactivation’ always represent a relative comparison between two, or 
more, cognitive conditions; they are not absolute measures of neural activity during novel 
encoding or fixation baseline. Nonetheless, functional imaging during memory tasks does 
provide the possibility of investigating brain function while the subjects are performing the 
types of cognitive processes that pose difficulties for MCI and AD patients in everyday life.  
Most of the earlier fMRI studies have focused on investigating hippocampal activation in 
MCI subjects and AD patients and comparing their results to those from healthy elderly 
subjects. The present results are consistent with the earlier reports of decreased or absent MTL 
activity during memory encoding in clinical AD patients (Rombouts et al. 2000, Machulda et al. 
2003, Sperling et al. 2003, Golby et al. 2005). Here, no significant MTL findings were observed in 
the spm2 between-group or correlational analyses. The negative MTL results in spm2 analyses 
may be explained by the combination of a large extent threshold (> 100 voxels) and a cluster-
corrected threshold (P < 0.05) as a sign of ultimate statistical significance. It was decided to use 
the same statistical thresholding for both the VBM and fMRI analyses, and this combination of 
extent and cluster thresholding was considered to be the most relevant for combining both 
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structural and functional analyses. Another possible explanation for the lower significance of 
the MTL results is that MCI subjects, particularly those with ‘early’ MCI, have been reported to 
show paradoxical increases in MTL activity (Dickerson et al. 2004, Hämäläinen et al. 2007a), 
which may increase the heterogeneity of the fMRI response patterns obtained within the MCI 
group. It appears possible that imaging of functional alterations in the posteromedial cortices 
may provide a more useful functional marker for clinical purposes than imaging of the MTL in 
early AD, particularly given the strong structure-function relationship with the entorhinal 
cortices revealed in the present study.  
A more recently introduced approach – functional connectivity MRI (fcMRI) – identifies 
brain systems via intrinsic functional (activity) correlations; it is very informative because it 
provides a means of assessing interacting brain regions during an awakened rest state in a 
manner that is independent of task-induced deactivation imaging (Damoiseaux et al. 2006, Fox 
et al. 2007, Greicius et al. 2003, Greicius et al. 2004, Wang et al. 2010). Recent fcMRI studies have 
corroborated the findings of altered task-induced deactivation in MCI subjects and AD patients 
relative to controls in a complementary way (Celone et al. 2006, Sorg et al. 2007, Supekar et al. 
2008, Wang et al. 2007, Zhou et al. 2008). As an example, the functional connectivity between 
the posteromedial and MTL cortices has been reported to be impaired even in MCI subjects in 
comparison to the corresponding situation in healthy elderly controls (Sorg et al. 2007, Zhou et 
al. 2008). Resting state fcMRI has also been demonstrated to reflect underlying structural 
connectivity between the MTL and posteromedial cortices, confirming results obtained by 
diffusion tensor imaging (Firbank et al. 2007, Zhou et al. 2008, Choo et al. 2010, Greicius et al. 
2009).  
6.2 EFFECT OF CHOLINERGIC STIMULATION IN EARLY ALZHEIMER’S 
DISEASE – FUNCTIONAL IMAGING DURING A RECOGNITION MEMORY TASK 
(STUDY 2)  
The findings of the present study provided evidence that patients with clinical AD, while 
performing a face recognition memory task, exhibited greater fMRI activity in several cortical 
brain areas during acute or chronic treatment with the ChEI, rivastigmine, in comparison to 
their performance in this task while receiving placebo. The difference in the patients’ fMRI 
activity during chronic rivastigmine versus placebo treatment was inversely correlated with 
their baseline cognitive status. In other words, poorer baseline cognition, as assessed by their 
MMSE score, was related to a greater fMRI signal increase during chronic medication treatment, 
particularly in the prefrontal and posteromedial cortices. In contrast, patients with better 
preserved cognitive abilities demonstrated less enhanced regional cortical activity during 
chronic cholinergic medication. These results imply that the prefrontal attention/working 
memory systems are already impaired in the early stages of AD. Furthermore, the effect of 
cholinergic medication in the brain areas involved in recognition memory processing depends 
on the severity of the disease and may present as increased or decreased fMRI activation 
patterns, as also suggested in earlier phMRI studies in MCI and AD patients.  
The participants in the present study were newly-diagnosed clinical AD patients who had 
not been previously treated with psychoactive medication, thus providing pure placebo results 
as baseline. The placebo and acute experiments were randomized in a double-blind manner and 
the time interval between the experiments was 1 week. Therefore, placebo and learning effects 
caused by imaging order can be excluded in these placebo and acute experiments. In the chronic 
treatment condition, fMRI was conducted 4 weeks after the placebo and acute experiments. It 
was assumed that the long time interval between experiments decreased the possibility of any 
residual learning effects affecting task performance, or that the patients would have changed 
their response strategy between imaging sessions. The stability of each individual study 
subject’s memory strategy is also supported by the observation that the changes observed in the 
fMRI response pattern that were most evident between the placebo and chronic medication 
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were also evident between placebo and acute medication conditions. These findings suggest 
that this task can be used to detect significant differences in brain activation between placebo 
and acute as well as in chronic medication conditions. 
In the present study, alterations in fMRI activity were not related to statistically significant 
changes in task performance as measured by reaction times, recognition hits, or false alarms. In 
previous studies, improved task performance and less demanding cognitive processing have 
been associated with decreased fMRI signal intensity and more focused brain activity in regions 
critical to the task performance (Furey et al. 2000, Gur et al. 1988, Just et al. 1996). The present 
study sample was relatively small, and therefore future studies with larger sample sizes are 
warranted to replicate and corroborate these results. A larger sample size, possibly combined 
with an event-related fMRI task design, would also enable a more thorough investigation of the 
relationship between medication, possible changes in cognitive/ task performance, and the 
underlying fMRI activation pattern.  
One of the advantages of phMRI is its possibility ability to evaluate a drug response while 
the individuals are performing the type of task in which they are clinically impaired. On the 
other hand, functional imaging of AD patients with compromised cooperation may be 
challenging. Therefore, for the purposes of the present study, a relatively simple cognitive task 
was used that required both attentional and complex working memory processing, i.e. 
functions known to be impaired in clinical AD, but at the same time providing a feasible task 
for mild AD patients to perform.  
During the actual moment of comparison of the first and second faces of the fMRI face 
recognition paradigm, the patients displayed significant fMRI activation in the bilateral 
fusiform, prefrontal and cingulate cortices, as well as in the medial temporal lobe structures and 
the cerebellum. This network was activated during placebo, acute, and chronic treatments, in 
agreement with findings from earlier studies (Haxby et al. 1996, Kanwisher et al. 1997, Clark et 
al. 1996, Sperling et al. 2001, Crane et al. 2002, Zeineh et al. 2003). It is noteworthy that even 
healthy elderly individuals tend to show different activation patterns in the bilateral prefrontal 
cortices compared to young subjects performing a similar task (Cabeza et al. 1997). Thus, the 
patients in this study were largely utilizing brain areas that would be expected to be activated 
during face recognition memory paradigms. When comparing fMRI findings between imaging 
sessions, both acute and chronic treatment elicited stronger fMRI activity, particularly in the 
prefrontal cortical areas in comparison to the corresponding placebo exposure, consistent with 
previous reports of increased prefrontal activity during cholinergic stimulation in AD patients 
(Kaasinen et al. 2002, Stefanova et al. 2006). Furthermore, the fMRI signal intensity, particularly 
in the prefrontal cortices, was inversely correlated with the baseline MMSE score, whereas age, 
education, or medial temporal lobe/cortical atrophy did not correlate with the baseline MMSE 
score in this relatively small group of clinical AD patients (mean MMSE 22, range 16 - 27). 
Finally, it was decided to administer a fixed medication dose, which might not have been the 
optimal dose for treatment. Future studies with longer clinical and imaging follow-up will be 
needed to investigate the possibility of using baseline fMRI results in combination with other 
measures to distinguish potential drug responders from non-responders.  
Previous studies have revealed that visual signal processing is modulated according to task 
demands (Büchel  et al. 1998). The locus of this modulation appears to be upstream in the 
sensory processing pathways, compatible with the ‘early selection’ theories of selective 
attention (Treisman et al. 1980). This kind of modulation presupposes that there is an 
interaction between sensory input and modulatory ‘top-down’ influences from other cortical 
areas (Fink et al. 1996, Rees et al. 1997) and, furthermore, that these 'top-down' influences can be 
affected by the cholinergic system (Furey et al. 2008). In the present study, the difference in the 
fMRI activation pattern in the prefrontal cortex as well as in occipital visual areas between 
chronic and placebo treatments was significantly negatively correlated with the MMSE score 
while the subjects were performing the face recognition task. This may indicate that improved 
attention patients with higher MMSE scores are able to more effectively trigger the early 
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neuronal processing steps of visual information, leading to less effortful processing 
requirements in the prefrontal cortices. This hypothesis is supported by findings from earlier 
studies (Furey et al. 2008, Pariente et al. 2005, Gu et al. 2002) indicating that the decline in 
activity in the prefrontal areas can be attributed to a restoration of attention by cholinergic 
stimulation. The general attentional system is affected by cholinergic stimulation in both 
healthy subjects and AD patients (Bentley et al. 2008, Gu et al. 2002). On the other hand, one 
could speculate that the increased fMRI activation in the prefrontal cortex is most probably 
associated with the failing attentional system, which in turn may increase the amount of visual 
signaling and thus the processing of this information would place a further burden on the 
working memory. This is in agreement with the fact that AD patients utilize frontal 
compensatory networks (Gould et al. 2006, Woodard et al. 1998) and working memory is linked 
to attentional processing (Baddeley 1993). The fMRI signal is primarily considered to be a 
measure of the neuronal input and local processing of information within a given brain region. 
ChEIs may also affect regional cerebral blood flow through the cholinergic innervation of 
blood vessels (Rees et al. 1997, Furey et al. 2008). However, the pharmacologic effects mediated 
through neurovascular coupling are unlikely to be the sole explanation for the differential fMRI 
responses between two different task conditions, such as face recognition vs baseline, reported 
in this study. 
6.3 LONG-TERM RESPONSE TO CHOLINESTERASE INHIBITOR TREATMENT 
TO fMRI RESPONSE IN AD (STUDY3) 
The present results suggest that increased the fMRI activation achieved by cholinergic 
stimulation in brain areas normally activated by the visual face recognition task is associated 
with a better clinical response to ChEI, whereas uninhibited fMRI activation spreading to brain 
areas not associated with the task performance was indicative of non-functional brain networks 
which would be unable to improve cognitive function after cholinergic stimulation. Thus, 
phMRI may be useful for identifying those AD patients likely to respond to treatment with ChE 
inhibitors. 
The average MMSE scores remained stable at the 6 and 12 months’ follow-ups when 
compared to baseline values, which is in accordance with earlier studies showing unaltered 
MMSE scores in patents using rivastigmine for 2 years (Minthon et al. 2009, Stefanova et al. 
2006). In addition, according to Sun et al. (Sun et al. 2008), patients benefit from ChEI for 14 
months on average until their MMSE score declines by 2 points or more. Correspondingly, 
according to historical data, the natural decline on the MMSE score for patients with mild to 
moderate AD without medication is approximately 2-4 points per year (Courtney et al. 2004, 
Small et al. 2005, Winblad et al. 2001). Thus, the present follow-up results are in accordance 
with earlier studies i.e. on average, these patients benefitted from the treatment.  
At the 12 months’ follow-up, 16 patients were still receiving rivastigmine; due to tolerability 
issues one patient was on donepezil and one on galantamine. The patient treated with 
donepezil had a stable MMSE score at the 12 months’ follow-up when compared to baseline, 
while the patient with galantamine had declined by 1 MMSE point. It is not possible to make 
any comparison between different ChEI preparations in this study due to the low number of 
subjects. The main results of this study did not change when patients receiving atypical 
antipsychotics, such as quetiapine, were excluded. 
The fMRI results have been described in more detail in a previous report (Miettinen et al. 
2011). In the present study, the focus was placed on examining the correlation between ChEI 
induced fMRI changes and MMSE score difference between baseline and 12 months’ follow-up. 
The most evident positive correlation both during acute and chronic cholinergic stimulation 
was found in right prefrontal cortex, which is in agreement with the concept that this brain area 
is involved in face recognition (Haxby et al. 1996). The increased activation in processes 
participating in face recognition may be a reflection of a well functioning regulation of the 
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attentional system according to the task demands. Well functioning brain networks may be 
essential if one wishes to obtain a positive ChEI response. 
The negative correlation in both acute and chronic cholinergic stimulation was found in the 
left prefrontal cortex and left fusiform gyrus. Thus, the patients with the worst ChEI response 
had increased fMRI activation in areas not associated with task performance. It is considered 
that this phenomenon is caused by failing brain networks rather than being due to some kind of 
compensatory activation. In healthy young subjects, the face-specific brain area is located 
mostly in the right fusiform gyrus (Clark et al. 1996, Kanwisher et al. 1997) and face recognition 
activates also right prefrontal, bilateral parietal and ventral occipital areas (Haxby et al. 1996). 
The functional connectivity of the right fusiform gyrus to the prefrontal cortex and left fusiform 
gyrus declines as a result of AD pathology (Clark et al. 1996, Bokde et al. 2006). As the 
cholinergic deficits also present in primary visual cortex (Kanwisher et al. 1997) are influenced 
by ChEI, the failing attentional regulation may cause uncontrolled hyperactivation in non-
specific areas. The finding of negative correlation in the left fusiform gyrus and left prefrontal 
cortex is most likely attributable to non-functional brain networks, which are unable to control 
activation according to task demands. Cognitive function requires a high level of functional 
interactions between the regions in the network supporting cognition, and when these networks 
are not functioning properly, cognition cannot be improved by ChEI treatment. 
As a consequence of the asymmetry in the fMRI finding, it was decided to study the 
association between fMRI signal intensity difference between the right and left fusiform gyri on 
chronic cholinergic treatment and MMSE score difference between baseline and 6 / 12 months’ 
follow-up. A higher signal intensity in the right versus left fusiform gyri correlated significantly 
with the MMSE score increase during follow-up and 14.3 / 31.6 % of the total variance in MMSE 
score difference between baseline and the 6 / 12 months’ follow-up was explained by the linear 
regression model. In addition, a higher signal intensity in right versus left fusiform gyri 
predicted a response to ChEI treatment with increasing MMSE scores during the follow-up with 
77.8 / 77.8 % sensitivity and 88.9 / 77.8 % specificity. During cholinergic treatment, the 
functional attentional system would increase activation in the right fusiform gyri, while a non-
functioning system would also increase activation in the left fusiform gyrus in an uncontrolled 
manner. Thus the changes in the signal intensity difference logically depend on the 
functionality of the attentional system. 
There are some limitations to this study. The number of patients was small, and thus the 
results cannot be directly generalized. The patients were not randomized for the chronic 
treatment because randomizing would have caused an unacceptable delay before starting the 
AChI treatment. However, the fMRI results using acute treatment were congruent to those 
obtained after chronic treatment (figures 6-7, Table 13-14). Another limitation to this study is 
that the patients were not treated with the same ChEI, i.e. at the 12 months’ follow-up, 18 were 
receiving rivastigmine, one was being treated with galantamine and one with donepezil. 
However, the results indicate that the effect of ChEIs on cognition depends on the functional 
integrity of the attentional system. The fMRI signal is primarily considered to be a measure of 
the neuronal input and local processing of information within a given brain region. ChEIs may 
also affect regional cerebral blood flow through the cholinergic innervation of blood vessels 
(Furey et al. 2008, Rees et al. 1997). The pharmacologic effects mediated through neurovascular 
coupling are unlikely to be the sole explanation for the differential fMRI responses between two 
different task conditions, such as face recognition vs baseline, reported in this study. The fMRI 
activation related to the button press itself was unlikely to cause any significant response, 
because the region of interest was not one known to be activated by motoric function. The use 
of MMSE as a measure of cognition may oversimplify the overall changes achieved by ChEI on 
brain function as a whole. However, the effect of AD to cause a deterioration in the MMSE score 
as a function of disease process is well known and because of the rather small number of 
patients in this trial, it showed most significant correlations in the present analysis. Even though 
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a lack of deterioration may be regarded as response, it was decided to define responders as only 
those patients showing a clear MMSE improvement compared to baseline.   
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7 CONCLUSIONS 
1. The results of the first study demonstrated that both the structure of the entorhinal 
cortex and the function of the posteromedial cortices were  affected early in the course 
of AD, and suggested that these findings were strongly correlated. Thus, the 
evaluation of structural and functional alterations of the strongly interconnected 
entorhinal and posteromedial cortices may represent potential tools for early 
identification of AD. 
2. The findings of the second study provided evidence that patients with clinical AD, 
while performing a face recognition memory task, show greater fMRI activity in 
several cortical brain areas during acute and chronic treatment with the ChEI, 
rivastigmine, in comparison to the situation while they were given placebo. The study 
indicated that the prefrontal attention/working memory systems were impaired in the 
early stage of the AD and that the effect of cholinergic stimulation, as reflected by the 
altered fMRI activity during a recognition memory task, depended on the clinical 
severity of the disease. Further, the effect of cholinergic medication in the brain areas 
involved in recognition memory processing is dependent on the severity of the disease 
and may present as increased or decreased fMRI activation patterns as also postulated 
in earlier phMRI studies in MCI and AD patients. 
3. The third study indicated that the increased fMRI activation occurring after 
cholinergic stimulation in brain areas normally activated by the visual face recognition 
task was associated with a better clinical response to ChEI, while uninhibited fMRI 
activation spreading to brain areas not associated with the task performance was 
evidence of non-functional brain networks which were unable to improve cognitive 
function in response to cholinergic stimulation. In other words, phMRI may be useful 
for identifying those AD patients likely to respond to cholinergic treatment. The 
phMRI method used in this study may have clinically important applications in the 
study of future pharmacologic agents, especially in conditions where a novel 
medication would be expensive, perhaps needing to be administered as an infusion or 
alternatively it could be rather toxic. 
In the future, it would be optimal to identify incipient AD at a minimally symptomatic state 
i.e. before irreversible alterations in brain structure have occurred. This would leave scope for 
the use of potential novel treatment options. fMRI may be useful in early diagnostics as well as 
for understanding mechanisms of  action of novel AD therapies. Advances in the therapeutics 
and development of biomarkers for AD, even those achieving small delays in disease 
progression, would clearly reduce both the individual and global burden of the disease. 
Nonetheless, much more research will be needed before one can expect to see major 
breakthroughs in the early diagnosis and treatment of AD.  
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Pekka Miettinen
Functional Magnetic 
Resonance Imaging in 
Alzheimer’s Disease
There is a prolonged presymptomatic 
period, even lasting for decades, 
between the very first biochemi-
cal changes occurring in the brain 
until the appearance of the clinical 
symptoms of Alzheimer’s disease 
(AD). The purpose of this study was 
to advance our understanding of the 
morphological and pathophysiologi-
cal alterations in prodromal AD, and 
to contribute to the identification of 
potential magnetic resonance imag-
ing markers for early interventions 
in AD.
